



Published in final edited form as:

Chem Rev. 2008 May ; 108(5): 1708–1731. doi:10.1021/cr078215f.

The Chemical Neurobiology of Carbohydrates

Heather E. Murrey and Linda C. Hsieh-Wilson*

Division of Chemistry and Chemical Engineering and Howard Hughes Medical Institute, California Institute of Technology, Pasadena, California 91125

1. Introduction

The cell surface displays a complex array of oligosaccharides, glycoproteins, and glycolipids. This diverse mixture of glycans contains a wealth of information, modulating a wide range of processes such as cell migration, proliferation, transcriptional regulation, and differentiation.^{1–5} Glycosylation is one of the most ubiquitous forms of post-translational modification, with more than 50% of the human proteome estimated to be glycosylated.⁶ Glycosylation adds another dimension to the complexity of cellular signaling and expands the ability of a cell to modulate protein function. The structural complexity of glycan modifications ranges from the addition of a single monosaccharide unit to polysaccharides containing hundreds of sugars in branched or linear arrays.⁷ This chemical diversity enables glycans to impart a vast array of functions, from structural stability and proteolytic protection to protein recognition and modulation of cell signaling networks.^{8,9–12}

Emerging evidence suggests a pivotal role for glycans in regulating nervous system development and function. For instance, glycosylation influences various neuronal processes, such as neurite outgrowth and morphology, and may contribute to the molecular events that underlie learning and memory.^{7,13,14} Glycosylation is an efficient modulator of cell signaling and has been implicated in memory consolidation pathways.^{15–18} Genetic ablation of glycosylation enzymes often leads to developmental defects and can influence various organismal behaviors such as stress and cognition.^{19–24} Thus, the complexity of glycan functions help to orchestrate proper neuronal development during embryogenesis, as well as influence behaviors in the adult organism.

The importance of glycosylation is further highlighted by defects in glycan structures that often lead to human disease, as exhibited by congenital disorders of glycosylation (CDG).^{25–29} These are usually inherited disorders resulting from defects in glycan biosynthesis, which are accompanied by severe developmental abnormalities, mental retardation, and difficulties with motor coordination. Such disorders highlight the importance of glycan biosynthesis in human health and development. Because therapeutic treatments are currently limited, investigations into the structure–activity relationships of glycans, as well as disease-associated alterations to glycan structure, are crucial for developing strategies to combat these diseases.

Understanding the structure–function relationships of glycans has been hampered by a lack of tools and methods to facilitate their analysis. In contrast to nucleic acids and proteins, oligosaccharides often have branched structures, and their biosynthesis is not template-encoded. As such, the composition and sequence of oligosaccharides cannot be easily predicted, and genetic manipulations are considerably less straightforward. Analytical techniques for investigating oligosaccharide composition, sequence, and tertiary structure are still undergoing development and are far from routine, unlike methods for DNA and protein analysis. Lastly, glycan structures are not under direct genetic control and, thus, are often heterogeneous. This heterogeneity complicates structure–function analyses by traditional biochemical approaches that rely on the isolation and purification of glycans from natural sources.

The problems associated with oligosaccharide analysis have hindered efforts to understand the biology of oligosaccharides yet have given chemists a unique opportunity to develop new methods to overcome these challenges. The development of chemical tools for the analysis of glycan structure and function is essential to advance our understanding of the roles of glycoconjugates in regulating diverse biological processes. In this review, we will highlight the emerging area of glyconeurobiology with an emphasis on current chemical approaches for elucidating the biological functions of glycans in the nervous system.

2. Sialic Acids

2.1. Structure

Sialic acids participate in a multitude of biologically interesting phenomena, including cell–cell recognition, adhesion, and intracellular signaling events.^{30–32} Originally known as neuraminic acid (Neu) and its derivatives, sialic acids are a family of α -keto acids containing a nine-carbon backbone.³² The most well-known members of the sialic acid family include *N*-acetylneuraminic acid (Neu5Ac), *N*-glycolylneuraminic acid (Neu5Gc), and deaminoneuraminic acid (KDN) (Figure 1). In addition to these basic forms, more than 50 distinct sialic acid structures have been identified in nature, arising from acetylation, methylation, lactylation, sulfation, and phosphorylation of the C-4, C-5, C-7, C-8, or C-9 hydroxyl groups.

Sialic acids exist predominantly as terminal monosaccharides linked to galactose residues in glycan chains through $\alpha(2-3)$ - or $\alpha(2-6)$ -linkages. They can also form a ho-mopolymer of $\alpha(2-8)$ -linked sialic acid in mammals, termed polysialic acid (PSA).^{33,34} As discussed below, each glycoform dictates a unique function to the glycoproteins and glycolipids expressing these sugars. Sialic acids have historically received much attention due to their participation in cell–cell recognition events and the pathogenesis of diseases such as cancer,^{35–37} inflammatory disease,^{38–40} and viral infection.^{41–44} The development of sialic acid analogues as inhibitors or probes for biomedical research has led to significant advances in our understanding of this important family of carbohydrates. Here, we will discuss some of the roles of sialic acids in neurobiology and chemical approaches that have provided insight into their functions.

2.2. Neurobiological Functions

2.2.1. $\alpha(2-3)$ -Sialic Acid and Myelin-Associated Glycoprotein—Sialic acid is often expressed as $\alpha(2-3)$ -linked sialic acid in the nervous system, a carbohydrate motif recognized by the Siglec (sialic acid-binding immunoglobulin-like lectin) family of proteins. Human Siglecs include at least 13 members, each containing a common V-set immunoglobulin domain that interacts with sialic acid.⁴⁵ One interaction that has been extensively studied is the binding of myelin-associated glycoprotein (MAG; also known as Siglec-4) with $\alpha(2-3)$ -sialic acid. MAG is a 100-kDa integral membrane glycoprotein that is expressed myelinating glia cells.^{46,47} It is involved in regulating the formation and maintenance of myelin⁴⁸ and has been suggested to inhibit nerve regeneration in the adult central nervous system (CNS).⁴⁹⁻⁵¹ Mice deficient in MAG display delayed myelination,⁵² defects in the organization of periaxonal space,⁵³ and subtle morphological abnormalities of myelin sheaths.⁵² The interactions of MAG with sialic acid-containing glycosphingolipids, known as gangliosides, have been extensively studied and have contributed to our understanding the role of MAG in myelin formation and neural regeneration.

MAG preferentially binds the glycan structure Neu5Ac $\alpha(2-3)$ Gal $\beta(1-3)$ GalNAc,⁵⁴ which is expressed on cell-surface gangliosides and *O*-glycans of glycoproteins.⁴⁷ Gangliosides represent the major source of sialic acid expression in the brain. MAG binds with high affinity and specificity to the major brain gangliosides GD1a and GT1b, as well as the polysialoganglioside GQ1ba, a minor ganglioside expressed on cholinergic neurons (Figure 2). Digestion of gangliosides purified from bovine brain with neuraminidase, an enzyme that cleaves sialic acid residues, eliminated the binding of MAG to these gangliosides, demonstrating the importance of the sialic acid moiety in mediating MAG–ganglioside interactions.⁵⁵⁻⁵⁷

Studies suggest that the association of MAG with sialic acid-containing gangliosides plays an important functional role in neuronal growth. The ability of MAG to inhibit neurite outgrowth *in vitro* is blocked by treatment of cerebellar granule neurons with neuraminidase or with the glucosyl-ceramide synthase inhibitor P4, which prevents synthesis of all glycosphingolipids.⁵⁵ Moreover, mice lacking the glycosyltransferase gene GalNAcT (UDP-*N*-acetylgalactosamine: GM3/GD3 *N*-acetylgalactosaminyltransferase) do not express complex gangliosides such as GD1a and GT1b and, as a consequence, exhibit axon degeneration and gross dysmyelination.^{58,59} These mice also display progressive behavioral abnormalities consistent with neurodegenerative disease, such as defects in balance, reflexes, and motor coordination.⁵⁹ Thus, detailed knowledge of MAG and its interactions with sialylated glycans may enhance our understanding of myelinating disorders such as multiple sclerosis and provide opportunities to enhance axon regeneration after CNS injury or disease.

2.2.2. Polysialic Acid—In the brain, PSA is expressed primarily on the protein neural cell adhesion molecule (NCAM).⁶⁰⁻⁶² NCAM plays critical roles in both nervous system development and memory formation, regulating processes such as cell adhesion, axon targeting and fasciculation, neuronal migration, synaptic plasticity, and synaptogenesis.^{60,61,63-70} PSA–NCAM is highly expressed in the embryonic brain⁷¹⁻⁷³ and

is found in the adult brain in areas that retain a high degree of plasticity and neurogenesis, such as the hippocampus, olfactory bulb, and hypothalamus.^{74–77}

Although the molecular mechanisms underlying PSA function are not well understood, PSA is thought to modulate cell–cell adhesion by attenuating homophilic NCAM–NCAM interactions. The large steric bulk and hydration shell of the carbohydrate chain increase the intercellular space by 10–15 μm , reducing *trans* NCAM–NCAM interactions across apposing cells.⁷⁸ In addition, PSA modulates the interactions of NCAM with other proteins, such as heparan sulfate proteoglycans involved in the formation and remodeling of hippocampal synapses.⁷⁹ The PSA chains on NCAM have also been proposed to play a role in some neuropsychiatric disorders. For example, expression of PSA–NCAM is significantly reduced in the hippocampus of schizophrenic patients and may contribute to the complex symptoms associated with the disease.^{80–82} Moreover, PSA has been implicated in the etiology of Alzheimer's disease, as PSA–NCAM-positive granule cells are increased in the hippocampus of Alzheimer's patients and are associated with disorganization of PSA-positive fibers.⁸³ Finally, PSA may also regulate neuronal function through NCAM-independent mechanisms. For example, PSA has been suggested to act as a competitive antagonist of the NMDA receptor, an ionotropic glutamate channel involved in synaptic transmission,⁸⁴ thereby preventing glutamate-induced excitotoxicity.⁸⁵

Despite intriguing roles for sialic acid-containing glycans, the molecular mechanisms underlying their diverse functions in the brain remain largely unknown. As described below, chemical approaches to access and manipulate sialic acid structures have expanded our understanding of the neuro-biological roles of sialic acid and promise to continue to advance the field.

2.3. Chemical Neurobiology of Sialic Acid

2.3.1. Synthetic Sialic Acid Derivatives: Probing the Specificity of MAG

Interactions—Synthetic sialic acid analogues have been used to elucidate the molecular determinants important for MAG-ganglioside interactions. The C-9 hydroxyl group represents a key recognition element: substitution of this group with hydrogen, halogen, or thiol groups attenuated the association of MAG with Neu5Ac (Figure 3, compounds **1–5**). Interestingly, an amino group at C-9 enhanced binding to MAG by 3-fold, suggesting the importance of a hydrogen donor at this position (compound **6**).⁸⁶ The C-5 *N*-acetyl group of Neu5Ac was also found to be critical for MAG binding, although it is not always required for interaction with other Siglecs. Replacement of this group with an *N*-propanoyl, *N*-aminoacetyl, or *N*-thioacetyl moiety enhanced binding of sialic acid to MAG by up to 4-fold (compounds **7–9**). The corresponding halogenated derivatives were all found to increase the binding to MAG (compounds **10–13**), with the monofluorinated derivative achieving a 17-fold increase in potency. In contrast, amino substitution at the C-5 position significantly attenuated binding to MAG.⁸⁶ Together, these studies highlight key interactions between MAG and the C-9 hydroxyl and C-5 *N*-acetyl groups of sialic acid.

In addition to probing monosaccharide variants, numerous oligosaccharide derivatives have been synthesized and tested for binding to MAG. These structures mimic naturally occurring ganglioside structures such as GD1a (Figure 2). Consistent with previous studies,

substitution of the C-9 hydroxyl of Neu5Ac with a methyl group within the trisaccharide Neu5Ac α (2–3)Gal β (1–4)Glc attenuated binding to MAG by 5-fold, again highlighting the importance of the glycerol side chain.⁸⁷ These results are consistent with an X-ray crystal structure of the Siglec sialoadhesin complexed with sialyllactose, in which the C-9 hydroxyl group of NeuAc forms a hydrogen bond with the amide backbone of Leu-107.⁸⁸ Although these proteins are distinct, it is conceivable that their mode of binding to sialic acid would be conserved across Siglec family members. In contrast to C-9, the C-7 and C-4 hydroxyls do not appear to contribute substantially to the binding energy of MAG–sialic acid interactions.⁸⁷ The C-7 deoxy derivative of Neu5Ac α (2–3)-Gal(β 1–4)Glc β -2-azidoethyl exhibited only slightly enhanced binding to MAG (1.5-fold), whereas the C-4 deoxy derivative showed slightly decreased binding (2-fold). However, both the C-7 and C-4 hydroxyls appeared to be critical for binding when placed in the context of a polyvalent array.⁵⁷ Thus, valency and cell-surface presentation may reflect another facet of the complex regulation and specificity of Siglec–ganglioside interactions.

Synthetic oligosaccharide derivatives have also provided insight into the importance of specific glycosidic linkages and other residues within the structure. MAG was found to bind 5-fold better to α (2–3)-linked Neu5Ac than to α (2–6)-linked Neu5Ac in synthetic trisaccharides.⁸⁷ Interestingly, replacement of Neu5Ac in a pentasaccharide structure with the naturally occurring sialic acid KDN led to a 6.5-fold increase in MAG binding,⁸⁷ suggesting that other sialic acid forms may bind MAG *in vivo*. In addition to contacts with terminal sialic acid residues, internal sugars were also found to be important for MAG interactions. For instance, substitution of the C-4 hydroxyl group of galactose in Neu5Ac α (2–3)-Gal β (1–4)Glc with a hydrogen atom enhanced binding to MAG by 2.3-fold. Changing this residue to GalNAc, adding an *O*-methyl substituent at C-6, or exchanging the ring oxygen to an *N*-methyl or *N*-butyl functionality decreased the potency of the trisaccharide.⁸⁷ Modifications of the third glucose residue to *N*-acetylglucosamine (GlcNAc) also decreased the binding properties of the molecules. Various substitutions of the *N*-acetyl group, such as *N*-phthaloyl or *N*-octanoyl substituents, increased the potency of the compounds, which reflects the potential for a hydrophobic interaction with MAG at this site.⁸⁷ Lastly, pentasaccharides of the structure Neu5Ac α (2–3)Gal β (1–4)AlINAc β (1–3)-Gal β (1–4)Glc β -2-(trimethylsilyl)ethyl (AlINAc = *N*-acetyl-allosamine) were found to increase binding above the trisaccharide Neu5Ac α (2–3)Gal β (1–4)Glc by ~6-fold, suggesting even more extensive contacts between MAG and the interior residues of large glycan structures.⁸⁷

Together, studies using synthetic analogues have illustrated how subtle perturbations to the sialic acid core structure can have significant effects on protein binding. As described below, such studies may facilitate the design of novel synthetic inhibitors of MAG function with therapeutic potential.

2.3.2. Development of MAG Antagonists with Therapeutic Potential—The importance of MAG–ganglioside interactions for nerve regeneration and myelination has inspired the design and synthesis of small molecules capable of disrupting those interactions. Such molecules have the potential to enhance nerve regeneration by blocking the inhibitory

effects of MAG on neurite outgrowth. Below, we provide some examples of small molecule antagonists that exhibit activity in cellular regeneration models.

Paulson and co-workers examined the interactions of monovalent sialic acid derivatives with MAG and other Siglec family members.⁸⁹ Over 25 derivatives representing most of the major sialic acid structures found on glycoproteins and glycolipids were tested. The most potent inhibitor of MAG–ganglioside interactions was the disialyl structure Neu5Ac α (2–3)Gal β (1–3)[Neu5Ac α (2–6)]GalNAc α -O-ThrOCH₃ (Figure 4A), which exhibited an IC₅₀ value of 0.3 μ M. This compound showed greater than 12000-fold enhanced potency relative to Neu5Ac for inhibiting MAG–sialic acid interactions.⁸⁹

The disialyl structure above and other potent inhibitors such as Neu5Ac α (2–3)Gal β (1–3)GalNAc were subsequently tested for their ability to attenuate MAG-mediated inhibition of neurite outgrowth.⁹⁰ When rat cerebellar granule neurons (CGN) are cultured on a substratum of myelin-extracted proteins, they project fasciculated axons and cluster together, leaving the majority of the substrata bare. This form of neuronal growth inhibition is mediated primarily by MAG. The sialosides relieved the MAG-dependent inhibition of CGN neurons, enhancing nerve regeneration in a dose-dependent manner and proportional to their relative binding affinities for MAG.⁹⁰ The most potent compound, the disialyl structure, completely reversed the inhibition induced by MAG. Thus, synthetic glycans can effectively enhance neurite outgrowth *in vitro* and, when used in combination with other treatments, may provide a means to improve functional recovery after neuronal injury. The ability to compare various Siglec family members against a large number of sialoside structures has also revealed the specificity of Siglecs for different carbohydrate epitopes and may help to fine-tune the development of selective MAG antagonists.

Many oligosaccharide-based inhibitors are synthetically challenging to produce and can suffer from poor pharmacokinetics. As an alternative to this approach, Ernst and coworkers generated structurally simplified mimics of the ganglioside GQ1ba. In particular, the Gal and GalNAc residues in the trisaccharide Neu5Ac α (2–3)Gal β (1–3)GalNAc were replaced with an α -linked benzyl ether moiety, and aromatic residues were positioned on the glycerol side chain (Figure 4B). Despite its smaller size, this compound displayed a remarkable 1000-fold enhanced binding affinity relative to the trisaccharide Neu5Ac α (2–3)Gal β (1–3)GalNAc β -2-(trimethylsilyl)ethyl. Although the compound was not tested in cellular regeneration assays, it was anticipated to have improved pharmacokinetic properties due to its lower molecular weight and favorable Clog *P* value.^{91–93} Similar approaches may yield additional therapeutic leads with the desired inhibitory potency and pharmacokinetics for the treatment of demyelinating disorders.

2.3.3. Synthetic Mimics of α (2–8)-Linked PSA for Nerve Regeneration—PSA expression is generally considered a permissive determinant in areas of neuronal growth and plasticity, making it a potential therapeutic target for neuronal regeneration. In fact, expression of PSA has been shown to promote functional recovery and provide a favorable environment for axonal regeneration in animal models of spinal cord injury.^{94,95} In these studies, PSA–NCAM was ectopically expressed in spinal cord astrocytes *in vivo*,⁹⁴ or PSA-expressing Schwann cell grafts were employed.⁹⁵ Although the use of PSA oligo- and

polysaccharides may be viable alternatives, PSA isolated from natural sources is often heterogeneous in length and can be contaminated with other cell-surface glycans. In addition, PSA adopts a helical conformation⁹⁶ and forms filament bundles,⁹⁷ thus exhibiting different structural elements that may have distinct functions.

To circumvent these challenges, Rougon, Schachner, and co-workers screened a large peptide library to identify potential PSA mimetics.⁹⁸ Two cyclic peptides were identified that recapitulated the properties of endogenous PSA. Both compounds stimulated the outgrowth and defasciculation of mouse dorsal root ganglion (DRG) neurons and promoted neuronal migration *in vitro* and *in vivo*. In addition, one peptide enhanced the migration of transplanted neuronal progenitor cells in the murine olfactory bulb *in vivo* via a pathway known to be regulated by PSA.⁹⁸ Thus, synthetic mimics may provide novel alternatives to PSA for neuronal regeneration.

2.3.4. Metabolic Labeling To Remodel Cell-Surface Sialic Acid Interactions—

The metabolic labeling of glycan chains with unnatural sugars has played a key role in expanding the knowledge of sialic acid function in the nervous system. Early studies by Reutter and colleagues demonstrated that unnatural chemical functionalities could be incorporated into cell-surface sialylglycoconjugates by the addition of *N*-acetylmannosamine analogues (ManNAc; Figure 5A) to cells.^{99–103} ManNAc is the first committed intermediate in the sialic acid biosynthetic pathway, and the enzymes in this metabolic pathway are promiscuous for some unnatural substrates.^{104–106} As described below, the ability to alter the structures of sialylglycoconjugates has provided key insights into the roles of sialic acid in neuronal migration and proliferation.

2.3.4.1. Metabolic Labeling of Neurons with Elongated *N*-Acyl Derivatives of Sialic

Acid: Elongated *N*-acyl derivatives of ManNAc have been incorporated into sialylglycoconjugates of PC12 cells, oligodendrocyte progenitor cells, microglia, astrocytes, and neurons from cerebellar microex-plant cultures.^{101,107} In these studies, cells were treated with *N*-propanoylmannosamine (ManNProp), wherein the *N*-acetyl substituent of Neu5Ac is replaced with a longer *N*-propanoyl group (Figure 5A). ManNProp was found to stimulate the proliferation of microglia relative to cells treated with the natural sialic acid precursor, ManNAc.¹⁰⁷ ManNProp also induced the migration of oligodendrocyte progenitor cells, the precursors to oligodendrocyte cells, which play key roles in myelin formation and become functionally impaired in neurological diseases such as multiple sclerosis.^{108–112} Interestingly, treatment with ManNProp prolonged expression of a sialylated ganglioside involved in cell migration, the A2B5 epitope,¹¹³ revealing a potential mechanism for its functional effects.

In other studies, Reutter and co-workers investigated whether ManNProp modulates signaling pathways within oligodendrocytes.¹¹⁴ Treatment of these cells with ManNProp and the inhibitory neurotransmitter γ -aminobutyric acid (GABA) induced GABA-dependent oscillations in intracellular calcium. Calcium is an important second messenger in the nervous system, and calcium oscillations are believed to contribute to a highly plastic signaling system underlying the communication between neurons and glia.¹¹⁴ Interestingly, ionotropic GABA receptors are modified by sialic acid,^{115,116} suggesting that extended *N*-

acyl substituents may alter the functional properties of this receptor. However, ManNProp undoubtedly perturbs the expression of multiple sialylglycoconjugates at the cell surface, and direct evidence that altered sialylation of the GABA receptor is responsible for the observed response is lacking. In the future, it will be interesting to uncover the precise molecular mechanisms by which these modifications to sialic acid structure elicit their effects on intracellular signaling.

ManNProp has also been shown to promote neuronal growth in various contexts. For instance, ManNProp induced the neurite outgrowth of small rat CGN, PC12 cells, and chick DRG neurons.^{117,118} Moreover, treatment with Man-NProp promoted reestablishment of functional connections in the perforant pathway, which consists of projections from the entorhinal cortex into the dentate gyrus of the hippocampus, in coculture experiments.¹¹⁷ Although the particular glycoconjugates responsible for these effects were not elucidated, several cytosolic proteins implicated in neurite outgrowth were found to be differentially expressed after the ManNProp treatment, including unc-33 like phosphoprotein (ULIP), various heat shock proteins, and 14-3-3 ϵ , a protein that associates with both GABA receptors and the $\alpha(2-3)$ -sialyltransferase IV.^{117,119,120}

Bertozzi and colleagues have explored the influence of various ManNAc derivatives on PSA biosynthesis. *N*-Butanoylmannosamine (ManNBut, Figure 5A), but not ManNProp, was shown to significantly inhibit PSA expression in a dose-dependent manner in the NT2 neuroblastoma cell line. Moreover, both human polysialyltransferases responsible for PSA biosynthesis (STX and PST) displayed reduced kinetic efficiencies for transfer of ManNBut and ManNPent (Figure 5A), whereas ManNProp was transferred at a rate sufficient for biosynthesis.^{118,121} Thus, elongation of the *N*-acyl side chain of sialic acid may interfere with recognition of the growing PSA chain by polysialyltransferases. However, findings by Jennings and co-workers suggest that both ManNBut and ManNProp may be partially incorporated into sialylglycoconjugates, as detected by flow cytometry using a monoclonal antibody that recognizes *N*-propanoyl- and *N*-butanoyl-PSA.^{122,123} Consistent with an inhibitory effect on PSA biosynthesis, ManNBut blocked polysialylation of NCAM in both chick DRG neurons¹¹⁸ and NT2 cells¹²⁴ and decreased the outgrowth of DRG neurons.¹¹⁸ The effects on neurite outgrowth were comparable to those elicited by treatment of cells with endoneuraminidase, an enzyme that cleaves PSA residues.

2.3.4.2. Metabolic Labeling with ManNGcPA: Metabolic labeling of neurons with unnatural sugars has also been exploited to alter protein recognition events at the cell surface. Treatment of neuroblastoma–glioma hybrid cells with the sialic acid metabolic precursor *N*-glycolylmannosamine pentaacetate (ManNGcPA; Figure 5A) converted cell-surface sialylglycoconjugates from expressing Neu5Ac to expressing Neu5Gc,¹²⁵ a sialic acid form that is not normally found in humans.¹²⁶ Whereas Neu5Ac sialylglycoconjugates displayed on neuronal cells bound efficiently to MAG, the binding of MAG to cells expressing Neu5Gc sialylglycoconjugates was significantly inhibited.¹²⁷ These studies demonstrate the potential of metabolic labeling to serve as a useful tool for perturbing specific glycan–protein interactions.

2.3.4.3. Chemoselective Labeling of Sialylated Cell-Surface Glycoconjugates: The ability to incorporate unnatural sugar analogues into cell-surface glycoconjugates allows for the introduction of reactive chemical functionalities onto glycoproteins and glycolipids, such as ketone, azide, or alkyne groups. These functionalities allow for selective labeling of proteins with reporter groups such as affinity tags and fluorescent dyes or for the delivery of toxins.^{128–131} Bertozzi and co-workers have exploited *N*-levulinoylmannosamine (ManLev), which contains a ketone functionality appended to the *N*-acyl side chain (Figure 5A), to label neuroblastoma cells.¹²⁹ Incubation of the cells with ManLev resulted in incorporation of the ketone moiety into sialylated glycans in a concentration-dependent manner. Subsequent reaction with a biotin hydrazide derivative (Figure 5B) enabled visualization of sialylglycans by fluorescence microscopy, revealing their presence along the cell body and neuronal processes.¹³² Although the specific sialyltransferases involved are not fully understood, ManLev was successfully incorporated into PSA, suggesting that $\alpha(2-8)$ -polysialyltransferases are capable of utilizing ketone-modified precursors for PSA synthesis.¹³² These studies provide a powerful means to modulate the structure of PSA and potentially other sialylglycans with a wide variety of chemical groups.

2.3.4.4. Summary of Sialic Acid Metabolic Labeling: Cumulatively, studies have demonstrated that unnatural ManNAc derivatives can be exploited to manipulate the structure of sialylated glycans on neuronal cell surfaces. These studies have revealed that subtle alterations in sialic acid structure can have striking consequences for PSA biosynthesis and biological phenomena such as neurite outgrowth, cell proliferation, and migration. In the future, these versatile chemical tools could be employed for visualization of dynamic neuronal processes *in vivo*, such as activity-dependent changes in the expression or localization of sialylglycans. The ability to engineer the glycan composition of cell surfaces and to selectively label sialylated glycans for imaging or other applications provides a powerful complementary approach to genetics and biochemistry.

3. α -L-Fucose

3.1. Structure and Biosynthesis

α -L-Fucose (6-deoxy-L-galactose; Fuc) is generally expressed as a terminal monosaccharide on N- and O-linked glycoproteins and glycolipids. As such, it often serves as an important molecular recognition element for proteins. Fucose is distinct from other naturally occurring sugars because it is a deoxyhexose sugar that exists exclusively in the L-configuration (Figure 6). A structurally diverse array of fucosylated glycans has been identified with fucose often linked to the C-2, C-3, C-4, or C-6 positions of the penultimate galactose in glycoconjugates or to the core GalNAc residue of N-linked glycans.¹ *O*-Fucosylation, the direct modification of serine and threonine residues by fucose, has also been observed on epidermal growth factor (EGF) repeats of glycoproteins such as Notch, a protein involved in cell growth and differentiation.¹³³ While fucose is not elongated in N-linked and O-linked glycans, *O*-fucose can be elongated by other sugars.¹

Given the structural diversity of fucosylated glycans, it is perhaps not surprising that more than a dozen different human enzymes are involved in the formation of Fuc linkages.¹ Two enzymes, FUT1 and FUT2, are dedicated to the synthesis of Fuc $\alpha(1-2)$ Gal glycans, an

epitope found on the ABO blood group antigens^{134–136} that has also been implicated in synaptic plasticity.^{13,137,138} A gene homologous to FUT1 and FUT2, called Sec1, contains translational frameshifts and stop codons that interrupt potential open reading frames and thus appears to be a pseudogene.¹³⁴ FUT3 catalyzes the synthesis of both $\alpha(1-3)$ - and $\alpha(1-4)$ -fucosylated glycans and can transfer fucose to both Gal and GlcNAc in an oligosaccharide chain, whereas FUT4–7 form only $\alpha(1-3)$ -fucosylated glycans.^{139,140} FUT8 and FUT9 generate Fu $\alpha(1-6)$ GlcNAc structures, with FUT8 generally catalyzing attachment of this structure to the core asparagine residue of N-linked oligosaccharides¹⁴¹ and FUT9 catalyzing its attachment to a distal GlcNAc of polylactosamine chains.¹⁴² FUT10 and FUT11 are putative fucosyltransferases that are reported to synthesize $\alpha(1-3)$ -fucosylated glycans based on sequence homology, although no functional studies have yet been performed.¹ Finally, POFUT1 and POFUT2, also known as *O*-fucosyltransferase 1 and *O*-fucosyltransferase 2, catalyze the direct fucosylation of serine and threonine residues within epidermal growth factor repeats.^{143,144}

3.2. Neurobiological Functions

Fucosylated glycans play important roles in various physiological and pathological processes, including leukocyte adhesion,^{145,146} host–microbe interactions,^{147,148} and neuronal development.^{149,150} They are prevalent on the glycolipids of erythrocytes, where they form the ABO blood group antigens that distinguish specific blood types.¹³⁶ Aberrant expression of fucosylated glycoconjugates has been associated with cancer,^{151–154} inflammation,^{145,155–157} and neoplastic processes.^{158,159} For instance, the fucosylated antigens, sialyl Lewis^X, sialyl Lewis^Y, and sialyl Lewis^B, are up-regulated in certain cancers and have been associated with advanced tumor progression and poor clinical prognosis.^{160–163} Moreover, deficiency in fucose leads to a congenital disorder of glycosylation type IIc in humans, also known as leukocyte adhesion deficiency type II (LAD II). This disorder results in the impairment of leukocyte–vascular epithelium interactions and is characterized by immunodeficiency, developmental abnormalities, psychomotor difficulties, and deficits in mental capabilities.¹⁶⁴

Although their roles in the brain are less well understood, fucosylated glycans have been implicated in neural development, learning, and memory. Here, we will highlight aspects of their biosynthesis and functional roles in the nervous system.

3.2.1. Neuronal Development—Fucose has been reported to play an important role in neural development. *O*-Fucosylation is essential for the activity of Notch, a transmembrane receptor protein that controls a broad range of cell-fate decisions during development.^{165–169} Studies suggest that fucose modulates Notch signaling either by inducing a conformational change in the protein or by interacting directly with Notch ligands.¹⁶⁸ Notch signaling is believed to be involved in neuronal progenitor maintenance, and governs the cell-fate decision between neuronal and glial lineages. Notch signaling may also contribute to the behavior of differentiated neurons and neuronal migration.¹⁷⁰ Genetic deletion of the POFUT1 gene is embryonic lethal in mice and causes developmental defects similar to those observed upon deletion of Notch receptors, including abnormal vasculogenesis, somitogenesis, and neurogenesis.^{171,172} These studies demonstrate the

importance of fucose in proper neuronal development and implicate Notch fucosylation as an important mediator of these events.

3.2.2. Learning and Memory—Multiple studies have suggested a role for fucosylation in learning and memory. For instance, the incorporation of fucose into glycoconjugates in the brain was significantly enhanced by task-dependent learning in both chicks and rats.^{173–176} Rats were trained in a brightness discrimination task, in which animals learned to enter a bright chamber while avoiding a dark one. Trained animals demonstrated an increase in [³H]-labeled fucose incorporation into glycoconjugates at synapses, the specialized sites of communication between neurons.¹⁷⁵ Moreover, exogenous application of L-fucose or 2'-fucosyllactose (Figure 6) enhanced long-term potentiation (LTP), an electrophysiological model for learning and memory, both *in vivo* and in hippocampal slices.^{177,178}

Fucose is highly enriched at neuronal synapses,^{13,179,180} where the majority of the fucosylated glycoconjugates exist as complex N-linked structures.¹⁸¹ Studies indicate that the activity of fucosyltransferases increases during synaptogenesis¹⁸² and upon passive-avoidance training in animals.¹⁸³ Moreover, the cellular machinery involved in protein glycosylation can be found within dendrites,^{184,185} raising the intriguing possibility that local protein synthesis and fucosylation may be occurring at synapses in response to neuronal stimulation.

Further studies have specifically implicated Fuca(1–2)Gal linkages in neuronal communication processes. For instance, 2-deoxy-D-galactose (2-dGal; Figure 6), which competes with native galactose for incorporation into glycan chains and thus prevents the formation of Fuca(1–2)Gal linkages,¹⁸⁶ has been shown to induce reversible amnesia in animals.^{138,186,187} In contrast, other small molecule sugars such as 2-deoxy-D-glucose, Gal, or Glc had no effect, suggesting a unique function for Fuca(1–2)Gal saccharides. 2-dGal has also been reported to interfere with the maintenance of LTP, both *in vitro* and *in vivo*.^{188,189} Furthermore, a monoclonal antibody specific for Fuca(1–2)Gal¹⁹⁰ significantly impaired memory formation in animals, presumably by blocking formation of the Fuca(1–2)Gal epitope.¹³⁷

3.3. Chemical Approaches for Studying L-Fucose

Despite intriguing evidence linking Fuca(1–2)Gal sugars to neuronal communication and memory storage, the molecular mechanisms by which these sugars exert their effects are not well understood. Recently, however, chemical tools have been developed that are beginning to shed light on the roles of Fuca(1–2)Gal lectins and glycoproteins in the brain.

3.3.1. Deoxygalactose Analogues—Hsieh-Wilson and co-workers investigated the effects of the amnesic compound 2-dGal and other fucosylation inhibitors on cultured hippocampal neurons. Inhibition of Fuca-(1–2)Gal linkages using 2-dGal led to stunted neurite outgrowth in young neurons lacking functional synapses (Figure 7).¹⁴ In contrast, 3-deoxy-D-galactose (3-dGal), which inhibits fucose incorporation at the C-3 position of galactose, had no effect on neurite growth, suggesting that specific fucose linkages are important for the neuritogenic activity. The effects of 2-dGal could be successfully rescued

by the addition of excess D-Gal to the media, suggesting that the inhibition can be reversed by the *de novo* synthesis of Fuca(1–2)Gal sugars.

Interestingly, 2-dGal also exerted dramatic effects on the morphology of older neurons, even after axonal differentiation and synaptogenesis had begun to occur.¹³ Application of 2-dGal led to a remarkable retraction of dendrites and collapse of synapses, whereas 6-dGal had no effect. However, D-Gal was only partially able to rescue the effects of 2-dGal, which may reflect the decreased plasticity of older neurons. Thus, fucosylated glycans and, in particular, Fuca(1–2)Gal glycoconjugates appear to be important for modulating neuronal morphology and maintaining functional neuronal connections.

To gain insight into the molecular mechanisms involved, Hsieh-Wilson and co-workers sought to identify Fuca(1–2)Gal glycoproteins in the hippocampus.¹³ Using a gel-based mass spectrometry approach, they identified synapsins Ia and Ib as the predominant Fuca(1–2)Gal glycoproteins in older hippocampal cultures and in the adult rat brain. The synapsins are synaptic vesicle-associated proteins that play important roles in neurotransmitter release and synaptogenesis.^{191,192} Fucosylation of synapsin I was found to have significant effects on synapsin expression in neurons, protecting it from proteolytic degradation by the calcium-activated protease calpain. Moreover, studies using 2-dGal and synapsin I-deficient mice showed that synapsin fucosylation contributes to the profound effects of 2-dGal on neurite outgrowth and synapse formation. However, other unknown Fuca(1–2)Gal glycoproteins were also involved in the process. These studies provide the first evidence that Fuca(1–2)Gal glycoproteins are directly involved in neurite outgrowth and underscore the importance of identifying the Fuca(1–2)Gal proteome of the brain.

3.3.2. Glycopolymers and Imaging Probes—Fucose often occupies a terminal position on glycan chains, and as such, it serves as an important molecular recognition element for lectins. A well-studied example is the binding of L-selectin to the fucosylated glycan sialyl Lewis^X, an interaction known to be critical for leukocyte adhesion.¹ To investigate whether Fuca(1–2)Gal lectins exist in the mammalian brain, a small molecule probe was designed and synthesized that contained the Fuca(1–2)Gal epitope and a biotin moiety for imaging potential lectin receptors in the brain (Figure 8).¹⁴ Rat hippocampal neurons were incubated with the small molecule probe, and the bound probe was visualized on the cells using a streptavidin–dye conjugate (Figure 8). Strong fluorescent staining of the cell body and neuronal processes was observed, consistent with the presence of fucose-binding lectin receptors.

To investigate whether the association of Fuca(1–2)Gal with these receptors would elicit a neuronal response, Hsieh-Wilson and colleagues treated cultured neurons with polyacrylamide-based polymers displaying multiple copies of the Fuca(1–2)Gal epitope.¹⁴ The Fuca(1–2)Gal polymers promoted neurite outgrowth by more than 75%, and the potency of the compounds was dramatically enhanced with increasing polymer concentration or carbohydrate valency. Importantly, polymers bearing other carbohydrate moieties, such as GlcNAc, Gal, Fuca(1–3)GlcNAc, or only Fuc, had no appreciable effects, indicating that the observed neuritogenic activity was specific for Fuca(1–2)Gal. Together, these studies provide the first evidence that Fuca(1–2)Gal lectin receptors are found in the brain, and they

identify a novel carbohydrate-mediated pathway for the regulation of neuronal growth. This work also highlights the power of chemical probes to explore the biological effects of specific glycans and their associated receptors. It will be important in the future to identify the lectins involved and to elucidate the specific mechanisms and pathways leading to neuronal growth.

3.3.3. Metabolic Labeling Using Alkynyl or Azido Fucose Analogues—Recently, the Bertozzi and Wong groups independently demonstrated that alkynyl- or azido-containing fucose analogues could be exploited to selectively label and image fucosylated glycans in mammalian cells.^{193,194} Their strategy exploits the fucose salvage pathway to convert unnatural fucose sugars into the corresponding GDP-fucose analogues, which then serve as donors for fucosyltransferases. Once the azido or alkynyl fucose analogue is incorporated into glycans, it can be reacted with fluorescent dyes, biotin, or peptides via Staudinger ligation or [3 + 2] azide–alkyne cycloaddition chemistry. Bertozzi and co-workers synthesized fucose derivatives with azido groups at the C-2, C-4, and C-6 positions.¹⁹³ Only the C-6 azido fucose analogue (Figure 6) was successfully incorporated into the glycans of the Jurkat T lymphocyte cell line, consistent with earlier observations that some fucosyltransferases tolerate substitutions at the C-6 position of the pyranose ring. Wong and colleagues demonstrated that both azido- and alkynyl-modified fucose derivatives (Figure 6) could be incorporated into the glycans of hepatoma cells, allowing for fluorescent imaging of fucosylated glycoconjugates.^{194,195} Interestingly, the alkynyl fucose analogue was shown to be significantly less toxic to cells than the azido fucose analogue.¹⁹⁴ Future application of these powerful approaches to neurons should facilitate proteomic studies to identify fucosylated glycoproteins and may allow for the dynamic imaging of protein fucosylation *in vivo*.

3.3.4. Summary of Fucosyl Oligosaccharides—Cumulatively, studies using chemical probes have revealed a role for fucosyl oligosaccharides and their associated lectins and glycoproteins in the regulation of neurite growth and synapse formation. These findings may shed light on behavioral and electrophysiological studies implicating Fuca(1–2)Gal in long-term memory storage. Alterations in neuronal morphology, such as dynamic changes in dendritic spine number and shape, occur during memory consolidation and LTP.^{196,197} One possibility is that the interaction between certain Fuca(1–2)Gal glycoproteins and lectins may promote the stabilization of synaptic connections that underlie learning and memory. In addition, fucosylation may exert its effects independently of lectins, by stabilizing fucosylated glycoproteins such as synapsin or modulating their functions. The continued development and application of chemical tools has tremendous potential to expand our understanding of the roles of fucosylated lectins and glycoproteins in the brain and may provide exciting opportunities to modulate neuronal communication processes.

4. O-GlcNAc Glycosylation

4.1. Structure and Biological Functions

O-GlcNAc glycosylation is the covalent attachment of β -*N*-acetylglucosamine to serine and threonine residues of proteins (Figure 9). Unlike other forms of glycosylation, *O*-GlcNAc is a dynamic, reversible modification found only on intracellular proteins, rendering it akin to protein phosphorylation. A wide range of proteins are *O*-GlcNAc-modified, including transcription factors, nuclear pore proteins, cytoskeletal proteins, and synaptic proteins.^{8,12,198,199–202} Several excellent reviews have described the functional roles of *O*-GlcNAc in transcription,²⁰³ apoptosis,^{204,205} signal transduction,¹⁹⁹ nutrient sensing,^{206,207} and proteasomal degradation.²⁰⁶ *O*-GlcNAc glycosylation has also been implicated in the cellular stress response^{208,209} and is induced by oxidative, osmotic, metabolic, and chemical stress.^{8,206} Levels of *O*-GlcNAc glycosylation are altered in disease states such as cancer, diabetes, and Alzheimer's disease.^{201,204,207,210–215} Moreover, one of the hallmarks of Alzheimer's disease is the formation of neurofibrillary tangles by hyperphosphorylated tau protein,²¹⁶ and several studies suggest that *O*-GlcNAc glycosylation negatively regulates the ability of tau to become phosphorylated.^{217,218} Thus, the investigation of *O*-GlcNAc function may provide insights into our understanding of critical cellular processes and diseases.

4.2. Neurobiological Functions of O-GlcNAc

Emerging evidence indicates an important role for *O*-GlcNAc glycosylation in the nervous system. The enzymes that catalyze the addition and removal of *O*-GlcNAc, *O*-GlcNAc transferase (OGT) and *O*-GlcNAcase (OGA), are most highly expressed in the brain²¹⁹ and are enriched in both pre- and postsynaptic nerve terminals.²²⁰ OGT expression is critical for cell survival,²²¹ and neuronal-specific deletion of the OGT gene in mice leads to abnormal development, defects in motor coordination, and early neonatal death.²²² Thus far, more than 50 neuronal proteins have been shown to be *O*-GlcNAc-modified, including proteins involved in transcription (e.g., CREB (cAMP-response element binding-protein), Sox2 (SRY box-containing gene 2), ATF-2 (activating transcription factor-2)), neuronal signaling (synGAP (synaptic Ras GTPase activating protein)), bassoon, the guanine nucleotide exchange factor PDZ-GEF, and synapsin I), synaptic plasticity (synaptopodin and δ -catenin), and neurodegenerative disease (tau and APP (β -amyloid precursor protein)).^{8,202,217,223–227} Finally, *O*-GlcNAc glycosylation levels are dynamically modulated by excitatory stimulation of the brain *in vivo* and upon activation of specific kinase pathways in cultured cerebellar neurons.²²³

Despite its importance, the functional roles of *O*-GlcNAc glycosylation are only beginning to be understood in the brain. A major challenge has been the difficulty of detecting and studying the modification *in vivo*. Similar to phosphorylation, *O*-GlcNAc is often dynamic, substoichiometric, targeted to subcellular compartments, and prevalent on low abundance regulatory proteins. The sugar is also both enzymatically and chemically labile. For example, mass spectrometry analyses to identify *O*-GlcNAc-modified proteins and map glycosylation sites are challenged by loss of the modification upon collision-induced dissociation (CID). The lack of a well-defined consensus sequence for OGT has precluded

the determination of *in vivo* glycosylation sites based on primary sequence alone. Furthermore, the complexity of the nervous system and its unique technical challenges (e.g., postmitotic cells, multiple cell types, blood–brain barrier, complex organization) greatly complicates efforts to study *O*-GlcNAc glycosylation and necessitates the development of rapid, highly sensitive detection methods. Here, we describe chemical approaches undertaken to overcome these challenges and highlight how they have advanced our understanding of the roles of *O*-GlcNAc glycosylation in neuronal function and dysfunction.

4.3. Chemical Tools To Study *O*-GlcNAc Glycosylation

4.3.1. Chemoenzymatic Labeling of *O*-GlcNAc Proteins

4.3.1.1. Rapid, Sensitive Detection: Traditional methods for detecting *O*-GlcNAc-modified proteins often suffer from limited sensitivity and specificity. For instance, radiolabeling of the proteins using UDP-[³H]-galactose and $\beta(1-4)$ -galactosyltransferase (GalT), an enzyme that transfers [³H]-galactose onto terminal GlcNAc groups of glycoproteins,²²⁸ can require weeks for visualization and lacks the sensitivity to detect certain *O*-GlcNAc-modified proteins. Lectins²²⁸ and antibodies^{229,230} are also effective methods, but they bind only a subset of the *O*-GlcNAc-modified proteins (usually those with multiple glycosylation sites) and have limited affinity and specificity.

In response, a chemoenzymatic approach for tagging *O*-GlcNAc proteins was developed by Hsieh-Wilson and coworkers that allows for more rapid and sensitive detection. An unnatural substrate for GalT was designed, in which a bioorthogonal ketone moiety was appended to the C-2 position of galactose (UDP-ketogalactose probe, Figure 10A).²³¹ Studies by Qasba and colleagues had demonstrated that a mutant form of GalT (Y289L) tolerates minor substitutions at this position.²³² Once transferred, the ketone moiety can be reacted with an aminoxy biotin derivative, thus permitting the sensitive detection of *O*-GlcNAc-modified proteins by chemiluminescence.²³¹ Notably, this method enables the identification of *O*-GlcNAc-glycosylated proteins that elude detection using other methods. For example, detection of the glycoproteins α -crystallin and CREB was accomplished within minutes, whereas lectins and antibodies failed to detect the modification on these proteins and tritium labeling required more than a week to develop.²³¹ Thus, this chemoenzymatic approach provides superior sensitivity relative to traditional methods and accelerates the identification of new *O*-GlcNAc-modified proteins.

4.3.1.2. Identification of *O*-GlcNAc-Glycosylated Proteins from Cells: Selective biotinylation of proteins using the chemoenzymatic approach also facilitates the parallel purification of *O*-GlcNAc-modified proteins from cell or tissue extracts by affinity chromatography.²³³ Previous methods have necessitated purification of individual proteins prior to analysis, a tedious and time-consuming process. Using the chemoenzymatic approach, the tagged *O*-GlcNAc proteins can be isolated in a single step by streptavidin affinity chromatography and interrogated for modification in parallel by Western blotting.²³³ This strategy was used to demonstrate that the AP-1 transcription factors c-Fos and c-Jun, as well as the activating transcription factor ATF-1, are *O*-GlcNAc-modified in HeLa cells.²³³ In addition, the identification of *O*-GlcNAc on CREB-binding protein (CBP) reveals a new class of *O*-GlcNAc-glycosylated proteins, the histone acetyltransferases

(HAT). Thus, glycosylation can be readily investigated across structurally or functionally related proteins, as well as novel functional classes. Together, studies have revealed that a broad number of transcriptional components are *O*-GlcNAc-glycosylated,^{202,223,233} and *O*-GlcNAc may function as a general regulatory modification for the control of transcription.^{239,240}

4.3.1.3. Proteome-Wide Analyses: When used in conjunction with high-throughput mass spectrometry, the chemoenzymatic approach can be exploited for proteome-wide analyses of *O*-GlcNAc-modified proteins.²⁰² Proteins from cell lysates are chemoenzymatically labeled and proteolytically digested. The desired glycopeptides are then captured by avidin affinity chromatography and analyzed by HPLC in line with tandem mass spectrometry (LC-MS/MS). The ketogalactose-biotin tag facilitates the isolation of *O*-GlcNAc glycopeptides from complex mixtures. This enrichment step is often crucial for detecting low-abundance post-translational modifications. The tag also provides a unique signature on the mass spectrometer, thus enabling unambiguous identification of *O*-GlcNAc-modified peptides and mapping of glycosylation sites to specific functional domains within a protein. Using this approach, Hsieh-Wilson, Peters, and colleagues reported the first proteome-wide identification of *O*-GlcNAc-modified proteins from the mammalian brain.²⁰² Nearly 100 peptides were identified containing the mass spectrometry signature, and 34 of these peptides were successfully sequenced. The sequenced peptides identified 25 different proteins from rat brain. Of the proteins identified, only two proteins had been previously reported, and 23 were novel *O*-GlcNAc-glycosylated proteins, thus significantly expanding the repertoire of proteins known to be modified.

This method demonstrates the power of chemical-tagging approaches to accelerate the high-throughput identification of *O*-GlcNAc glycoproteins. Notably, many of the proteins identified have important functional roles in gene regulation, cytoskeletal dynamics, neuronal signaling, and synaptic plasticity. For example, synaptopodin, synGap, and shank2 (SH3 and multiple ankyrin repeat domains protein 2) are critical for the regulation of dendritic spine formation.²³⁴⁻²³⁶ Synaptopodin and δ -catenin have important roles in learning and memory,^{234,237} and the guanine nucleotide exchange factor PDZ-GEF is involved in the assembly of signal transduction complexes at the synapse.²³⁸ Together, these studies suggest that *O*-GlcNAc glycosylation may play a role in mediating neuronal communication and signaling networks. Consistent with this observation, Burlingame and coworkers recently employed lectin weak-affinity chromatography in conjunction with mass spectrometry to identify 18 *O*-GlcNAc-glycosylated proteins from the postsynaptic density fraction of rat brain.²²⁴ The proteins represent multiple functional classes, and several proteins involved in synaptic vesicle cycling were found to be extensively *O*-GlcNAc-glycosylated, such as bassoon, piccolo, and synapsin I.²²⁴

While the chemoenzymatic approach has broad application to the study of *O*-GlcNAc-glycosylated proteins from cell and tissue extracts, *O*-GlcNAc proteins cannot be labeled in animals using this method. In addition, the determination of exact glycosylation sites is still difficult, because the ketogalactose-biotin moiety can be lost upon CID in the mass spectrometer. Instead, *O*-GlcNAc modification sites are mapped to short amino acid sequences within proteins, which still provides insight into the function of the modification.

Despite these limitations, the chemoenzymatic labeling strategy is so powerful for *in vitro* analysis and proteomics that a variation of this approach is now commercially available for fluorescent labeling or biotinylation of *O*-GlcNAc-glycosylated proteins using [3 + 2] cycloaddition chemistry (Figure 10B).

4.3.2. Metabolic Labeling of *O*-GlcNAc Proteins

4.3.2.1. Incorporation of GlcNAz into *O*-GlcNAc Proteins: A complementary strategy that enables tagging of *O*-GlcNAcylated proteins in living cells involves metabolically labeling the proteins with unnatural GlcNAc derivatives. Bertozzi and colleagues demonstrated that *N*-(2-azidoacetyl)-glucosamine (GlcNAz, Figure 10C) is processed by enzymes in the hexosamine salvage pathway, resulting in incorporation of a bioorthogonal azide functionality into *O*-GlcNAc-glycosylated proteins.²⁴¹ The azido group can be subsequently labeled with triarylphosphines via the Staudinger ligation. Using this approach, the authors demonstrated successful incorporation of GlcNAz into both nuclear and cytoplasmic proteins of cultured Jurkat T lymphocyte cells. In particular, selective labeling and detection of the nuclear pore protein p62, a known *O*-GlcNAc-modified protein with >10 glycosylation sites,²⁴² was shown using a phosphine-FLAG probe. Although incomplete labeling of *O*-GlcNAc-glycosylated proteins limits the sensitivity of this approach relative to the chemoenzymatic strategy described above, metabolic labeling with GlcNAz sugars can be performed in living cells and might allow for the dynamic imaging of *O*-GlcNAc-glycosylated proteins *in vivo*.

4.3.2.2. Proteomic Analysis by Metabolic Labeling: Although metabolic labeling has not yet been applied to neurons, it represents another powerful chemical approach for the high-throughput identification of *O*-GlcNAc-modified proteins. Zhao and colleagues labeled *O*-GlcNAc proteins in the HeLa cervical cancer cell line with GlcNAz and tagged them with a biotin phosphine reagent (Figure 10C).^{243,244} Tryptic digestion of the affinity-captured proteins, followed by LC-MS/MS analysis, led to the identification of 199 putative *O*-GlcNAc-modified proteins. Because the presence of the GlcNAc moiety was inferred rather than detected directly, independent confirmation of the modification by immunoblotting was required and demonstrated on 23 of the 199 proteins.

While this method provides a powerful chemical tool for profiling *O*-GlcNAc-modified proteins, there are some limitations of this procedure for *in vivo* labeling in the brain. Most sugars do not cross the blood-brain barrier,²⁴⁵ and thus *in vivo* labeling with these molecules would entail invasive surgical procedures for intracranial administration rather than simple intraperitoneal injection. In addition, metabolic labeling is not quantitative, which may limit the sensitivity of detection as well as preclude the ability to monitor glycosylation dynamics. Despite these limitations, the approach has been successfully employed to investigate the *O*-GlcNAc proteome in both mammalian and insect cell lines.^{243,244} In the future, metabolic labeling could prove a useful tool for studying the *O*-GlcNAc proteome in cultured neurons.

4.3.3. Methods for Mapping Exact Glycosylation Sites

4.3.3.1. The β -Elimination Followed by Michael Addition with Dithiothreitol (BEMAD)

Approach: The identification of *O*-GlcNAc modification sites within proteins is critical for elucidating the functions of *O*-GlcNAc in specific biological contexts. Nonetheless, the exact sites of glycosylation remain unknown for most proteins. Mapping glycosylation sites has been challenging due to the low abundance of the modification and the lability of the glycosidic linkage during fragmentation on a mass spectrometer, which can result in the loss of direct amino acid identification. Hart and co-workers showed that the labile GlcNAc moiety could be replaced with a more stable sulfide adduct by alkaline-induced β -elimination followed by Michael addition with dithiothreitol (BEMAD, Figure 11).²⁴⁶ The resulting sulfide adduct is not cleaved upon CID, thereby allowing sites of glycosylation to be more readily determined. However, a limitation of this approach is that it is often destructive to proteins,^{247,248} and selectivity controls must be performed to distinguish among *O*-GlcNAc, *O*-phosphate, and other O-linked carbohydrates.²⁴⁶ When biotin pentylamine is used in place of dithiothreitol, *O*-GlcNAc-modified peptides can be selectively biotinylated, enriched by affinity chromatography, and identified by LC-MS/MS analysis. This method has been successfully employed to identify novel *O*-GlcNAc sites on purified glycoproteins such as synapsin I and proteins from a purified rat brain nuclear pore complex.²⁴⁶ Further extension of BEMAD to complex mixtures for the high-throughput mapping of *O*-GlcNAc sites is an important future goal.

4.3.3.2. Electron Transfer Dissociation (ETD) and Electron Capture Dissociation (ECD) Coupled with Lectin Affinity Chromatography or Chemoenzymatic Labeling:

Recently, the development of novel fragmentation methods for mass spectrometry has facilitated the identification of *O*-GlcNAc modification sites. Electron transfer dissociation (ETD) and electron capture dissociation (ECD) use thermal electrons to produce sequence specific-peptide fragmentation without the loss of labile post-translational modifications such as *O*-GlcNAc and *O*-phosphate.²⁴⁹ ECD has recently been used by Burlingame and co-workers to identify *O*-GlcNAc glycosylation sites following enrichment of the modified peptides by lectin weak-affinity chromatography.²²⁴ The authors were able to identify glycosylation sites on several neuronal proteins such as spectrin $\beta 2$, shank2, bassoon, and piccolo.

While ECD requires the use of a Fourier transform mass spectrometer, ETD has the advantage of being performed in appropriately modified ion trap mass spectrometers, rendering the technology powerful and more accessible. Hsieh-Wilson, Coon, and colleagues have implemented ETD fragmentation to map glycosylation sites on neuronal proteins following chemoenzymatic labeling and enrichment by avidin affinity chromatography. The authors identified glycosylation sites on multiple proteins such as the neuron-specific transcriptional repressor BHC80, the transcriptional repressor p66 β , the transcriptional coactivator SRC-1, and the zinc finger RNA-binding protein.²²³ With further methodological refinements and advances in database search algorithms for fragment ions, it is anticipated that ETD and ECD will become increasingly powerful tools for the study of *O*-GlcNAc glycosylation.

4.3.4. Monitoring O-GlcNAc Dynamics—Unlike most forms of protein glycosylation, *O*-GlcNAc glycosylation is reversible and dynamic. Several studies have shown that global *O*-GlcNAc levels in cells change within minutes of activation by specific extracellular stimuli.^{250,251} *O*-GlcNAc levels are also highly responsive to cellular glucose concentrations, as approximately 2–5% of all glucose is metabolized through the hexosamine biosynthesis pathway to generate UDP-GlcNAc.^{252–254} Furthermore, studies have suggested a potential interplay between *O*-GlcNAc glycosylation and phosphorylation in neurons. An inverse relationship between *O*-GlcNAc and *O*-phosphate was observed upon activation of protein kinase C (PKC) or cAMP-dependent protein kinase (PKA) in the cytoskeletal protein fraction of cultured cerebellar neurons.²⁵⁵ As described below, recent quantitative proteomics studies have shown that *O*-GlcNAc glycosylation is dynamically induced by excitatory stimulation of the mammalian brain *in vivo*.²²³ Finally, *O*-GlcNAc glycosylation is known to be dysregulated in multiple disease states and is believed to contribute to the etiology of certain diseases, such as diabetes, Alzheimer's disease, and cancer.^{207,252,256,257}

Despite considerable investigation, the specific proteins undergoing dynamic changes in glycosylation remain largely unknown. Moreover, the molecular mechanisms and signaling pathways involved in the regulation of OGT and OGA are poorly understood. As such, there is a great need to develop chemical tools to monitor changes in glycosylation on specific proteins and at specific modification sites in both normal and disease states. We describe below some of the chemical approaches that have been developed to address these challenges.

4.3.4.1. FRET-Based Sensors: Mahal and colleagues developed a fluorescence resonance energy transfer (FRET)-based sensor to investigate *O*-GlcNAc glycosylation dynamics in living cells.²⁵⁸ Their approach uses two fluorophores, enhanced cyan and yellow fluorescent protein, separated by a known OGT substrate domain and the bacterial *O*-GlcNAc lectin GafD (Figure 12). Upon *O*-GlcNAc glycosylation of the substrate domain, the GafD domain binds the carbohydrate moiety, bringing the fluorophores into close proximity and leading to a concomitant increase in FRET. The authors detected a significant increase in FRET from HeLa cells transfected with the sensor construct upon treatment with glucosamine or the OGA inhibitor PUGNAc (*O*-(2-acet-amido-2-deoxy-D-glucopyranosylidene)amino-*N*-phenylcarbamate, Figure 14).²⁵⁸ This biological sensor represents a promising tool for the investigation of *O*-GlcNAc glycosylation dynamics in response to a variety of cellular stimuli.

4.3.4.2. The Quantitative Isotopic and Chemoenzymatic Tagging (QUIC-Tag) Approach for Quantitative Proteomics: Hsieh-Wilson, Peters, and co-workers developed a method to probe dynamic changes in *O*-GlcNAc glycosylation using quantitative mass spectrometry-based proteomics.²²³ Their QUIC-Tag approach (quantitative isotopic and chemoenzymatic tagging) involves chemoenzymatically labeling proteins from two different cell states (e.g., normal versus diseased; stimulated versus unstimulated) with the keto-galactose–biotin group as described above (Figure 13).²²³ After proteolytic digestion, the resulting peptides are isotopically labeled with either heavy or light isotope tags using reductive amination

chemistry to distinguish the two populations. The peptides are subsequently combined, and the biotinylated *O*-GlcNAc peptides are captured using avidin chromatography. MS analysis reveals two ions for each glycosylated peptide (corresponding to each of the two isotopically labeled forms), and calculation of the peak areas measures the change in glycosylation level for each peptide. Importantly, as the observed peptides are sequenced using CID or ETD MS, the method identifies specific proteins undergoing dynamic changes in glycosylation and can be used to monitor changes at particular glycosylation sites within proteins.

This approach has advantages over other methods of *O*-GlcNAc detection. For instance, lectins and *O*-GlcNAc antibodies are typically used to detect only global changes in *O*-GlcNAc glycosylation by Western blotting and do not monitor individual glycosylation sites. Metabolic labeling using GlcNAz may alter the kinetic efficiency of *O*-GlcNAc transfer to protein substrates, as well as influx through the hexosamine biosynthesis pathway, which complicates efforts to quantify dynamic changes in response to cellular stimuli. In contrast, the QUIC-Tag approach is performed on denatured protein lysates and thus preserves the physiological glycosylation state of the protein without perturbing intracellular glycosylation pathways.

By this approach, *O*-GlcNAc glycosylation was found to be stimulated upon PUGNAc treatment of cortical neurons or kainic acid-induced excitatory stimulation of rodent brains *in vivo*.²²³ Robust changes in *O*-GlcNAc glycosylation were observed at specific sites on several proteins, whereas other modification sites remained unchanged, suggesting that *O*-GlcNAc is subject to complex regulation in neurons. For example, glycosylation of early growth response-1 (EGR-1), a transcription factor involved in long-term memory formation and cell survival,^{259,260} increased greater than 10-fold after kainic acid stimulation. Because the dynamic glycosylation site within EGR-1 lies within its transactivation domain, *O*-GlcNAc glycosylation may modulate the transcriptional activity of EGR-1 and modulate gene expression. Cumulatively, these studies indicate that *O*-GlcNAc glycosylation is reversible, subject to complex regulation, and induced by neuronal activity, which supports the notion that *O*-GlcNAc represents an important regulatory modification in the brain.

4.3.4.3. Stable Isotope Labeling with Amino Acids in Cell Culture(SILAC)Coupled with Affinity Chromatography: Recently, Hart and co-workers employed the SILAC (stable isotope labeling with amino acids in cell culture) method for quantitative proteomics²⁶¹ in conjunction with immunoaffinity chromatography to investigate the interplay between *O*-GlcNAc and phosphorylation in COS-7 kidney fibroblast cells.²⁶² Cells from two different states were labeled with either heavy or light isotopes of arginine and combined. Proteins of interest were subsequently isolated by affinity chromatography using a general *O*-GlcNAc antibody, resolved by SDS-PAGE, proteolytically digested, and analyzed by LC-MS/MS.

Using this approach, Hart and colleagues investigated the effects of lithium inhibition of glycogen synthase kinase-3 (GSK-3) on *O*-GlcNAc glycosylation levels. GSK-3 is involved in multiple intracellular signaling cascades and is implicated in the etiology of Alzheimer's disease, diabetes, and bipolar disorder, thus making it a desirable therapeutic target.^{263,264} The authors identified 10 proteins that were enriched after LiCl treatment, suggesting that

they underwent increases in *O*-GlcNAc glycosylation. The increases in glycosylation were confirmed on four proteins by immunoprecipitation. Interestingly, many proteins exhibited no change, and 19 proteins showed decreases in glycosylation. These studies suggest that a complex interplay exists between *O*-phosphate and *O*-GlcNAc within signaling networks.

Although this approach works well for dividing cells, SILAC is not amenable to tissues and quiescent cells such as neurons. In addition, the method does not readily enable direct detection of the *O*-GlcNAc modification, and thus independent confirmation by immunoprecipitation is required. Nonetheless, this approach provides another powerful strategy to investigate the cellular dynamics of *O*-GlcNAc glycosylation.

4.3.4.4. Small-Molecule Inhibitors of OGT and OGA: Traditional genetic approaches have revealed insights into the functions of OGT and OGA *in vivo*. For example, genetic deletion of the OGT gene in mice has revealed that OGT is critical for cell survival, and neuron-specific deletion of OGT results in defects in mouse embryogenesis, loss of locomotor control, and neonatal death.^{221,222} Although such studies have revealed an important role for these enzymes in neural development, investigations into the functions of *O*-GlcNAc remain challenging, particularly in adult animals. The development of small-molecule inhibitors for OGT and OGA has been actively pursued to enable direct temporal and spatial control over OGT and OGA activity.

Well-known small-molecule inhibitors of OGT such as alloxan (Figure 14) show multiple nonspecific effects such as inhibition of OGA and glucokinase,^{265,266} as well as formation of superoxide radicals.²⁶⁷ To develop better pharmacological agents, Walker and co-workers screened a library using a high-throughput, fluorescence-based assay and identified several novel compounds that inhibited OGT activity *in vitro*.²⁶⁸ Notably, the compounds selectively inhibited OGT but not MurG, a related enzyme that also uses UDP-GlcNAc as a substrate.

As PUGNAc, the most commonly used OGA inhibitor, suffers from nonspecific activity toward β -hexosaminidase,²⁶⁹ several groups are working to develop more selective inhibitors. The Vocadlo and Hanover groups have extended the *N*-acyl substituent of PUGNAc to generate inhibitors with 10-fold selectivity for OGA over β -hexosaminidase.^{269,270} van Aalten and colleagues developed a nagstatin derivative based the crystal structure of a bacterial OGA (Figure 14).²⁷¹ This molecule contains an isobutanamido group at the N8 position that improves selectivity by fitting into a pocket of the enzyme and a phenethyl group at the C2 position that interacts with a solvent-exposed tryptophan from bacterial OGA. More recently, the Hanover and Vocadlo groups independently developed novel OGA inhibitors based on the nonspecific hexosaminidase inhibitor GlcNAc-thiazaoline, by adding fluoro, azido, or alkyl substituents (Figure 14). The resultant inhibitors exhibited over 3000-fold selectivity for OGA over β -hexosaminidase.^{272,273}

The development of such compounds may enable the selective inhibition of OGT and OGA in cultured neurons, as well as *in vivo*. The ability to perturb *O*-GlcNAc enzymes and glycosylation levels with small molecules should reveal new information about the

functional roles of *O*-GlcNAc glycosylation in the nervous system, as well as facilitate the identification of signaling pathways that regulate OGT and OGA.

5. Glycosaminoglycans

5.1. Structure and Diversity

Glycosaminoglycans (GAGs) are sulfated, linear polysaccharides that represent a central component of the extracellular matrix (ECM) and are involved in a myriad of biological functions, including blood coagulation,^{274,275} angiogenesis,^{276–278} tumor growth and metastasis,^{279–281} neurite outgrowth,^{282–285} spinal cord injury,^{286–288} and development.^{289–291} They are composed of repeating disaccharide units containing a hexuronic acid sugar linked to a hexosamine sugar.^{292,293} There are several classes of GAGs (Figure 15), each of which are distinguished by backbone composition, including heparin and heparan sulfate (HS), chondroitin sulfate (CS), dermatan sulfate (DS), keratan sulfate (KS), and hyaluronic acid (HA). Heparin and HS contain D-glucosamine (GlcN) and either D-glucuronic acid (GlcA) or L-iduronic acid (IdoA) connected by $\alpha(1-4)$ and $\beta(1-4)$ linkages. In contrast, CS polymers contain *N*-acetylgalactosamine (GalNAc) instead of GlcNAc in alternating $\beta(1-3)$ and $\beta(1-4)$ linkages to GlcA, whereas DS polymers have both GlcA and IdoA linked to GalNAc. Heparin/HS and CS/DS are attached to proteins through O-linkages to serine residues via a GlcA $\beta(1-3)$ Gal $\beta(1-3)$ Gal $\beta(1-4)$ Xyl (Xyl = xylose) tetrasaccharide linker, forming glycoconjugates known as proteoglycans.^{294–296} KS is attached to proteoglycans through either N- or O-linkages. Hyaluronic acid is unique in that it is not protein-bound and is reportedly synthesized in the plasma membrane,^{296,297} whereas proteoglycans are synthesized in the Golgi apparatus.^{292,293}

In addition to having different backbone compositions, GAGs display remarkable structural variation through sulfation of various hydroxyl groups along the polysaccharide backbone (Figure 15). The sulfation patterns of GAGs are incredibly diverse, owing to the large number of potential sulfation sites and possible combinations of differentially sulfated disaccharides linked in tandem. For example, heparin and HS disaccharide units can be sulfated at the C-2 position of IdoA or the C-3 and C-6 positions of GlcN. The C-2 amine of GlcN can also be acetylated, sulfated, or unmodified. Similarly, CS can be sulfated at the C-4 and C-6 positions of GalNAc, as well as the C-2 and C-3 positions of GlcA. A simple HS disaccharide has 48 potential sulfated sequences, yielding tetrasaccharides with over 2300 possible sulfation sequences.

GAGs also vary in chain length from ~10 to 200 disaccharide units, with clusters of low and high sulfation along the polysaccharide backbone.²⁹⁸ Structural studies suggest that GAGs can adopt a variety of helical conformations, such as variance in helical pitch that may depend on the associated counterion.^{299,300} Further structural diversity is obtained from the conformational flexibility of the pyranose ring of IdoA, which exists in equilibrium between the chair and skew-boat conformations when sulfated at the C-2 position.²⁹⁸ Thus, the combination of different sequences, charge distributions, and conformations gives rise to tremendous chemical and structural diversity within glycosaminoglycan chains.

5.2. Neurobiological Functions

5.2.1. Neuronal Development—Evidence from genetic and biochemical approaches suggests that the sulfation patterns of GAGs are important for modulating their biological activity and can exert profound effects on organismal development. For instance, mutation of the *N*-deacetylase–*N*-sulfotransferase gene (*Ndst-1*) involved in HS biosynthesis inhibits growth factor signaling that disrupts normal embryonic development in *Drosophila*.²⁹⁰ HS and CS have been shown to interact with numerous growth factors and axon guidance proteins in a sulfation-specific manner.^{283,301–308} Moreover, the sulfation patterns of HS and CS change during the course of brain development,^{309,310} and specific CS sulfation patterns are differentially expressed in certain brain regions.^{311,312} The sulfation patterns of HS and CS are also organ- and age-specific, as is the expression of different sulfotransferases.^{309,310} Thus, HS and CS sulfation patterns in the brain are tightly regulated with the exquisite spatial and temporal control required for neuronal development.

5.2.2. Axon Guidance—In the developing nervous system, neurons are presented with a variety of molecular cues that guide axons to their proper targets. HS sulfation has been implicated in axon targeting through the interaction of the HS proteoglycan glypican-1 with Slit, a secreted protein important for axon guidance, axon branching, and neuronal cell migration.^{313,314} Slit repels axonal growth by binding to the Robo receptor.^{314,315} Removal of HS by heparinase treatment or addition of exogenous HS containing specific sulfation patterns inhibits Slit binding to Robo and abolishes the axonal repulsion mediated by Slit.^{304,315} These results suggest that HS and particular HS sulfation patterns play important roles in mediating the chemotropic actions of Slit. In other studies, HS sulfation was shown to be critical for neuronal outgrowth and axon guidance in *Caenorhabditis elegans*. Using genetic approaches, Hobert and colleagues demonstrated that certain neuronal subtypes require the HS-modifying enzymes C5-epimerase, 2-*O*-sulfotransferase, and 6-*O*-sulfotransferase for proper axon guidance.³¹⁶ Interestingly, other subclasses of neurons require only the C5-epimerase or 2-*O*-sulfotransferase, and some neuronal subtypes do not require any of the HS modifying enzymes. Cumulatively, these studies demonstrate that HS sulfation patterns play important roles in neuronal development and may encode axon guidance cues to direct neurons to their proper targets *in vivo*.

5.2.3. Spinal Cord Regeneration—Chondroitin sulfate proteoglycans (CSPGs) are crucial components of perineuronal nets, structures of ECM molecules surrounding the soma and proximal dendrites of certain neurons in the brain and spinal cord.^{317,318} CSPGs and other ECM molecules are recruited to sites of CNS injury and form a portion of the glia scar, a structure that inhibits axonal regeneration and contributes to permanent paralysis *in vivo*. Several groups have demonstrated the importance of CSPGs and their associated sugar chains in mediating neuronal inhibition after spinal cord injury. For instance, CSPGs have been shown to inhibit the neurite outgrowth of DRG and CGN neurons *in vitro*.^{319,320} Moreover, degrading CS chains with chondroitinase ABC (ChABC), an enzyme that cleaves CS into disaccharide units, reverses the inhibitory effects of CSPGs on neurite outgrowth.^{321,322} Most notably, Fawcett, McMahon, and colleagues discovered that ChABC digestion of CSPGs promotes spinal cord regeneration *in vivo*, with concomitant partial recovery of proprioceptive behaviors and locomotor skills in mice.^{323,324} These and other

studies indicate that CSPGs exert a crucial inhibitory role on neuronal regeneration and represent valid targets for therapeutic intervention. Such studies also underscore the importance of CS glycosaminoglycans in this process and the need to further understand the molecular mechanisms and sulfation patterns involved in directing their activity.

5.3. Challenges to the Study of GAGs

While GAGs play a fundamental role in many neurobiological processes, a molecular level understanding of the roles of specific sulfation sequences in mediating GAG functions is largely unknown. GAG biosynthesis is not template driven and lacks the proofreading capabilities of DNA biosynthesis, which results in greater chemical heterogeneity and structural diversity within GAG chains. Thus, GAGs purified from natural sources are often mixtures of compounds that contain different sulfation patterns and chain lengths. Characterization of these structures is challenging and is often described simply in terms of the percent composition of distinct sulfated disaccharide subunits. Little is known about the precise linear sequences of GAG polysaccharides, although methods to sequence short oligosaccharide sequences are becoming available.^{325–327} Given these challenges, the synthesis of homogeneous oligosaccharides containing defined sulfation sequences has the potential to significantly advance our understanding of the structure–activity relationships of glycosaminoglycans. Here, we will highlight chemical approaches that have helped to decipher the roles of GAGs in the nervous system and efforts to develop GAG-based therapeutics for neurodegenerative diseases.

5.4. Synthetic Molecules for Probing Structure–Activity Relationships

As described above, the sulfation patterns of GAGs are important for directing their neurobiological functions. Although genetic approaches have revealed crucial roles for GAGs in neural development, such experiments lead to global changes in sulfation throughout the carbohydrate chain, precluding the identification of specific sulfation motifs responsible for biological activity. The use of chemically defined small-molecule GAGs has provided insight into their neurobiological roles and demonstrated the importance of specific sulfation sequences in mediating GAG functions.

5.4.1. Synthesis of Glycosaminoglycans—Early work on glycosaminoglycans focused primarily on the synthesis of heparin oligosaccharides.^{328–336} Heparin has been used since the 1940s as an antithrombic agent, and a unique heparin pentasaccharide sequence was discovered in the 1980s as a potent factor Xa inhibitor.²⁹⁸ The first syntheses of heparin pentasaccharides required over 60 steps, produced heparin in relatively low yield, and were impractical for the development of synthetic drugs. Since then, the efforts of multiple laboratories have contributed methods that allow for efficient syntheses of heparin, HS, and their analogues.^{337–344}

GAGs are notoriously difficult to synthesize, requiring the formation of stereospecific glycosidic linkages, uronic acid donors and acceptors with low chemical reactivity, and sophisticated protecting group strategies to effect regioselective sulfation. Heparin, HS, and DS oligosaccharides also necessitate efficient syntheses of the challenging L-idopyranosyl sugar. The synthesis of GAGs has been summarized in several excellent reviews (see refs

337, 344–347) Recently, there has been great interest in generating libraries of sulfated compounds to probe the role of sulfation and identify biologically active sulfation motifs.^{2,285,339,340,342,348} In general, these approaches implement modular, convergent synthetic strategies that afford multiple sulfated structures from a common disaccharide synthon and thus minimize the number of steps.

Other strategies have employed chemoenzymatic routes to generate defined GAG oligosaccharides. Kobayashi and co-workers have capitalized on the promiscuity of hyaluronidase, an enzyme that normally catalyzes the hydrolysis of chondroitin *in vivo*, to effect glycosidic bond formation and generate GAG polymers.^{349–353} They were able to demonstrate the efficient polymerization of *N*-acetylhyalobiuronate [GlcA β (1–3)GlcNAc] and *N*-acetylchondrosine [GlcA β (1–3)GalNAc] derivatives to form HA and nonsulfated chondroitin, respectively, as well as unnatural chondroitin analogues.³⁴⁹ DeAngelis and colleagues have generated chimeric unsulfated GAG oligo- and polysaccharides through the use of hyaluronan and chondroitin synthases.³⁵⁴ Notably, Rosenberg and co-workers have developed a chemoenzymatic route toward the synthesis of a specific sulfated HS pentasaccharide that binds to antithrombin III.³⁵⁵ The authors used a nonsulfated polysaccharide obtained from *E. coli* as starting material and synthesized the final product using six recombinant sulfotransferases. This route achieved the synthesis of the sulfated structure in just six steps with at least a 2-fold greater yield relative to total chemical synthesis,³⁵⁶ although it was performed only on a milligram-scale. Thus, chemoenzymatic synthetic strategies can complement traditional synthetic approaches to provide facile, efficient methods to generate structurally defined natural and unnatural GAGs.

5.4.2. Effects of HS and DS Molecules on Neuronal Growth—Early studies of GAG function in the nervous system involved the use of GAGs purified from various biological sources, such as shark cartilage, bovine kidney, and the surface of tumor cells.^{357–360} For example, Prochiantz and Rousselet demonstrated that natural HS polysaccharides enhance axonal outgrowth, while inhibiting dendrite elongation. In contrast, DS polysaccharides favor the growth of both axons and dendrites.³⁵⁸ Small-molecule di-through hexasaccharides derived from HS and DS polysaccharides were found to have similar effects as the natural polysaccharides, providing the first evidence that the biological activity of GAGs can be recapitulated in short oligosaccharides.^{357,358}

5.4.3. Neuroactive Small-Molecule Chondroitin Sulfates—Paradoxically, CS has been shown to both stimulate and inhibit neuronal growth, depending on the cellular context.^{361–363} However, the molecules used in those studies were ~200 saccharides in length, poorly defined, and heterogeneously sulfated. To address whether specific sulfation patterns were important for neuronal growth, Hsieh-Wilson and colleagues used a modular strategy to synthesize pure, chemically defined CS-E, CS-C, CS-A, and CS-R tetrasaccharides (Figure 16).²⁸³ Tetrasaccharides bearing the CS-E motif were found to stimulate the outgrowth of various neuron types, including hippocampal and dopaminergic neurons.^{283,285} A tetrasaccharide was found to be the minimal motif required for activity, as CS-E disaccharides had no effect on neurite outgrowth.²⁸⁵ Furthermore, tetrasaccharides bearing other prominent CS sulfation patterns found in the brain, such as CS-C and CS-A,

had no significant growth-promoting activity, underscoring the importance of specific sulfation patterns in directing CS activity. Notably, the unnatural CS-R motif could not stimulate neurite outgrowth, despite having the same overall negative charge as CS-E.²⁸³ Thus, the precise arrangement of sulfate groups along the carbohydrate backbone is critical for the growth-promoting activity of CS, rather than nonspecific electrostatic interactions. Together, these results provide direct evidence for the existence of a “sulfation code” that dictates the neurobiological functions of CS.

5.5. Carbohydrate Microarrays for Studying GAG–Protein Interactions

Microarray technology has revolutionized the discovery of biological information obtained from both genomics and proteomics experiments. More recently, the advent of carbohydrate microarrays has made a similar impact on our understanding of protein–carbohydrate interactions.^{283,304,364–376} Carbohydrate microarrays provide a powerful tool for the rapid interrogation of these interactions in a high-throughput, chip-based format. They have also allowed for systematic investigations into the role of specific sulfation patterns in mediating the biological activities of GAGs.

5.5.1. Oligosaccharide Microarrays—As described above, studies using chemically defined oligosaccharides have implicated a tetrasaccharide bearing the CS-E sulfation motif as important for neurite outgrowth. To gain insight into the molecular mechanisms underlying its biological activity, the binding of various CS molecules to a panel of neuronal growth factors was examined using carbohydrate microarrays.²⁸³ CS oligosaccharides were synthesized with an allyl functionality at the reducing end of the sugar. Ozonolysis, followed by reaction with 1,2-(bisaminoxy)ethane converted the allyl group to an aminoxy functionality for rapid conjugation of the oligosaccharides to aldehyde-coated slides.^{283,374} Robotically printed glass slides were analyzed for the binding of CS-A, CS-C, CS-E, and CS-R tetrasaccharides to growth factors such as midkine, BDNF, and fibroblast growth factor-1 (FGF-1). Midkine is a growth factor involved in neural tissue development and repair,³⁷⁷ whereas BDNF is a neurotrophin involved in nervous system development, synaptic plasticity, and neurodegenerative disease.³⁷⁸ Both midkine and BDNF were found to preferentially interact with the CS-E tetrasaccharide over other sulfation motifs. In contrast, FGF-1 did not interact with any CS molecules, consistent with earlier observations and further corroborating the method.^{309,379} Importantly, the novel interactions identified using these microarrays were validated in cellular assays and demonstrated to be important for CS-E-mediated neuronal growth. Blocking midkine, BDNF, or their cognate receptors using selective antibodies inhibited the neurite outgrowth induced by CS-E tetrasaccharides. These studies illustrate the power of carbohydrate microarrays to elucidate molecular interactions and mechanisms involving specific GAG sequences.

Seeberger and co-workers have used oligosaccharide microarrays to study the binding of heparin di-, tetra-, and hexasaccharides to FGF-1 and FGF-2.^{371,380} Both heparin tetra- and hexasaccharides were shown to interact with these growth factors, consistent with the minimum structural requirements known to bind FGF-1 and FGF-2. In the future, it will be interesting to examine the interactions of a panel of neuronal growth factors with different sulfated HS analogues and to compare their binding to both sulfated HS and CS molecules.

5.5.2. Polysaccharide Microarrays—In addition to oligosaccharide microarrays, polysaccharide microarrays have been developed and exploited for the study of GAG function. Although the structures of polysaccharides are less well-defined, polysaccharide microarrays can be readily assembled from commercially available compounds and can provide valuable information. For instance, such microarrays have revealed key structural determinants responsible for protein binding, such as the importance of sulfation at specific positions.^{283,304,374} They have also enabled rapid comparisons across different protein families or functional classes, as well as between different GAG subclasses (e.g., HA, HS, CS, DS, KS), providing a more comprehensive investigation into protein-binding specificity.³⁰⁴ Using polysaccharide microarrays, Shipp and Hsieh-Wilson found HS to interact in a sulfation-dependent manner with axon guidance proteins, such as Slit2, netrin1, ephrinA1, ephrinA5, and semaphorin5B.³⁰⁴ Slit2 interacted preferentially with 6-*O*-sulfated and *N*-sulfated HS sequences. Furthermore, the sulfation preferences of Slit2 and netrin1 were validated in cellular assays using differentially sulfated HS polysaccharides, which were shown to inhibit Slit- and netrin-mediated axonal guidance and neuronal migration.

Cumulatively, these studies demonstrate the ability of carbohydrate microarray technologies to distinguish the influence of fine structural details such as sulfation pattern on GAG–protein interactions. This methodology also provides a powerful platform to rapidly screen thousands of carbohydrate–protein interactions, which can help to identify the proteins mediating the biological functions of GAGs and uncover the diverse biological functions governed by these extraordinary molecules.

5.6. Glycosaminoglycan-Based Therapeutics

Historically, heparin oligo- and polysaccharides are known for their therapeutic value for the treatment of blood coagulation and deep vein thrombosis (DVT). Studies on a synthetic sulfated pentasaccharide of heparin have helped to uncover the mechanism of heparin's anticoagulant activity and led to development of the drug Arixtra for the treatment of pulmonary embolism and DVT.³³⁷ The development of additional GAG therapeutic molecules is underway to create potential treatments for cancer metastasis, Alzheimer's disease, and axonal regeneration. Here, we review the current literature on GAGs as potential therapeutic agents for neurodegenerative disorders.

5.6.1. Prion Diseases—Transmissible spongiform encephalopathies are prion diseases characterized by vacuolation, amyloid plaques containing amyloid fibrils, and neuronal degeneration. These diseases include scrapie, bovine spongiform encephalitis (also known as “mad cow disease”), Kuru (human form of transmissible spongiform encephalitis), Creutzfeldt–Jakob disease (CJD), and Gerstmann–Straussler–Scheinker disease.³⁸¹ The prion protein is the main component of amyloid fibrils, which are similar to the β -amyloid fibrils characteristic of Alzheimer's disease.³⁸² These proteins generally induce conformational changes of the protein from α -helix to β -sheet, which leads to aggregation and formation of plaques.^{383,384} Thus, molecules that inhibit prion protein aggregation and plaque formation have potential therapeutic value.

Avila and co-workers have investigated the effects of sulfated polysaccharides (heparin, KS, and CS), as well as the unsulfated polysaccharide HA, on prion polymerization *in vitro*.³⁸⁵ Sulfated GAGs led to significant inhibition of prion polymerization through the direct interaction of these molecules with prion amyloid fibrils. No polymerization inhibition or neuroprotection was observed with HA, suggesting that sulfation is critical for the observed activity.³⁸⁵ Interestingly, differentially sulfated GAGs led to different morphologies of the resulting fibrils. However, the polysaccharides used were from natural sources and thus contained some degree of heterogeneity. Systematic studies with GAGs of defined length and sulfation pattern have not yet been performed and may reveal new molecules with optimal activity as potential treatments for prion diseases.

5.6.2. Alzheimer's Disease—Glycosaminoglycans have also been investigated as potential treatments for the pathogenesis and senile dementia associated with Alzheimer's disease. HS proteoglycans are believed to promote aggregation of the β -amyloid peptide and hence contribute to the disease pathogenesis.^{386–391} In addition, HS has been shown to protect β -amyloid aggregates from proteolytic degradation³⁹² and microglia phagocytosis in rodent brains,^{393,394} resulting in the persistence of amyloid deposits.³⁹⁵ Heparin also enhances the synthesis, secretion, and cleavage of the β -amyloid precursor protein (APP) *in vitro*, suggesting that heparin may contribute to amyloid fibril formation.³⁹⁶ Together, these studies suggest roles for GAGs in the etiology of Alzheimer's disease and new potential avenues for therapeutic treatment.

Low molecular weight (LMW) heparin fragments and heparin disaccharides have been examined for their ability to affect amyloidogenesis in Alzheimer's disease. These heparin fragments, especially heparin disaccharides, inhibit binding of heparin to the β -amyloid peptide, as well as heparin-stimulated APP secretion *in vitro*. All LMW fragments used in these studies were found to cross the blood–brain barrier in an *in vitro* cell culture model, whereas passage of polysaccharides was significantly inhibited.³⁹⁷ Injection of LMW heparins into rat brains has also been shown to attenuate protein toxicity due to tau,^{398,399} a microtubule-associated protein whose aggregation is associated with the pathogenesis of Alzheimer's disease.⁴⁰⁰ In addition, LMW heparins attenuate β -amyloid-mediated neurotoxicity and inflammation.⁴⁰¹ Thus, LMW heparin molecules and their derivatives might be useful therapeutic agents to prevent or slow the progress of amyloidogenesis associated with Alzheimer's disease.^{397,402}

Two sulfated LMW glycosaminoglycans and their derivatives are currently in clinical trials for the treatment of Alzheimer's disease and senile dementia, and one drug, Ateroid marketed by Cornelli Consulting, is currently sold in Europe and Asia. Ateroid is mostly composed of LMW heparin and is used for the treatment of old-age dementia, ischemic vascular dementia, and multi-infarct dementia. Alzhemed (tramiprosate; 3-amino-1-propanesulfonic acid) is a small synthetic GAG-based mimetic currently in phase III clinical trials that inhibits the formation of β -amyloid fibrils.⁴⁰³ Results have been promising from phase II clinical trials in patients with mild-to-moderate Alzheimer's disease, suggesting the potential of such approaches for the treatment of this disorder.

5.6.3. Future Challenges—Elucidating the molecular mechanisms governing the modes of glycosaminoglycan action, such as the presence of a “sulfation code”, will greatly facilitate the development of new therapeutics specifically targeted to treat disorders such as Alzheimer’s disease. In addition, recently identified glycosaminoglycan mimetics such as Alzhemed can improve the pharmacokinetic properties of the molecules and create superior therapeutic agents. Given the scope of the current chemical methodology to study GAGs and their interactions, GAG-based therapeutic molecules are becoming highly attainable and may prove effective avenues for the treatment of diseases. As in the case of Arixtra, understanding the structure–activity relationships of GAGs and the “sulfation code” may yield molecules with fewer off-target side effects and enhanced therapeutic properties.

6. Summary and Future Directions

The development of new chemical approaches to investigate the biological functions of carbohydrates has accelerated our understanding of glycan structures and their contributions to neurobiology, cell signaling, and disease. These studies have revealed crucial roles for glycans in mediating neuronal growth, adhesion, migration, and regeneration. In addition, studies have implicated carbohydrates in modulating cell signaling, gene expression, and synaptic plasticity. As glycans are involved in a myriad of biological functions, understanding glycan function should continue to provide key insights into the molecular mechanisms underlying fundamental neurobiological processes. Moreover, our ability to understand and manipulate such processes using small molecules and glycan mimetics holds promise for many neurological disorders for which there are currently little or no therapeutic remedies.

The emergence of chemical technologies for labeling, detection, synthesis, and mimicry are slowly becoming standard in the field for investigating glycan function, and many of these tools are now commercially available. The ability to screen high-throughput carbohydrate microarrays should reveal hundreds of new molecular interactions with growth factors and other proteins. Such technologies allow the ability to profile oligosaccharide–protein binding interactions in ways that had only previously been available for protein and DNA interactions. In addition, these arrays may be useful for diagnostic testing, because many glycans are dysregulated in various disease states. The ability to chemically tag oligosaccharides has revolutionized glycoproteomics, and we are just on the cusp of uncovering a wealth of new information in the coming years in relation to signaling pathways and disease states. Furthermore, the synthesis of oligosaccharides and glycan mimetics has revealed detailed information regarding the structure–activity relationships of glycans and should impact investigations into new drugs or pathways for therapeutic intervention. Lastly, these versatile chemical tools enable analysis of glycans and perturbations in glycan function *in vivo* that until now have been unprecedented. As the repertoire of chemical tools for investigating glycan functions expands, an increasing number of oligosaccharide-mediated signaling pathways may be targeted for therapeutic intervention. The study of glycan structures should also reveal new biomarkers for early detection of certain diseases, for monitoring disease progression, or for measuring drug efficacy. We are only at the beginning of what promises to be an exciting new era for the

field of glycomics, and there are many discoveries and applications still waiting to be explored.

Acknowledgments

We gratefully acknowledge support from the National Institutes of Health (Grant RO1 GM084724), National Science Foundation (Grant CHE-0239861), American Cancer Society (Grant RSG-05-106-01-CDD), Tobacco-Related Disease Research Program (Grant 14RT-0034), and Howard Hughes Medical Institute.

References

1. Becker DJ, Lowe JB. *Glycobiology*. 2003; 13:41–53.
2. Gama CI, Hsieh-Wilson LC. *Curr Opin Chem Biol*. 2005; 9:609–619. [PubMed: 16242378]
3. Rampal R, Luther KB, Haltiwanger RS. *Curr Mol Med*. 2007; 7:427–445. [PubMed: 17584081]
4. Gabius HJ, Andre S, Kaltner H, Siebert HC. *Biochim Biophys Acta*. 2002; 1572:165–177. [PubMed: 12223267]
5. Nishihira J. *Int J Mol Med*. 1998; 2:17–28. [PubMed: 9854138]
6. Apweiler R, Hermjakob H, Sharon N. *Biochim Biophys Acta*. 1999; 1473:4–8. [PubMed: 10580125]
7. Kleene R, Schachner M. *Nat Rev Neurosci*. 2004; 5:195–208. [PubMed: 14976519]
8. Rexach JE, Clark PM, Hsieh-Wilson LC. *Nat Chem Biol*. 2008; 4:97–106. [PubMed: 18202679]
9. Wujek P, Kida E, Walus M, Wisniewski KE, Golabek AA. *J Biol Chem*. 2004; 279:12827–12839. [PubMed: 14702339]
10. Rudd PM, Merry AH, Wormald MR, Dwek RA. *Curr Opin Struct Biol*. 2002; 12:578–586. [PubMed: 12464308]
11. Yamaguchi H. *Trends Glycosci Glycotechnol*. 2002; 14:139–151.
12. Wells L, Vosseller K, Hart GW. *Science*. 2001; 291:2376–2378. [PubMed: 11269319]
13. Murrey HE, Gama CI, Kalovidouris SA, Luo WI, Driggers EM, Porton B, Hsieh-Wilson LC. *Proc Natl Acad Sci USA*. 2006; 103:21–26. [PubMed: 16373512]
14. Kalovidouris SA, Gama CI, Lee LW, Hsieh-Wilson LC. *J Am Chem Soc*. 2005; 127:1340–1341. [PubMed: 15686343]
15. Sandi C, Rose SPR, Mileusnic R, Lancashire C. *Neuroscience*. 1995; 69:1087–1093. [PubMed: 8848097]
16. Salinska E, Bourne RC, Rose SPR. *Eur J Neurosci*. 2004; 19:3042–3047. [PubMed: 15182312]
17. Welzl H, Stork O. *News Physio Sci*. 2003; 18:147–150.
18. Murphy KJ, Regan CM. *Neurobiol Learn Mem*. 1998; 70:73–81.
19. Jaeken J, Matthijs G. *Annu Rev Genomics Hum Genet*. 2007; 8:261–278. [PubMed: 17506657]
20. Ohtsubo K, Marth JD. *Cell*. 2006; 126:855–867. [PubMed: 16959566]
21. Best T, Kempes E, Bryan J. *Nutr Rev*. 2005; 63:409–418. [PubMed: 16466077]
22. Kudo T, Fujii T, Ikegami S, Inokuchi K, Takayama Y, Ikehara Y, Nishihara S, Togayachi A, Takahashi S, Tachibana K, Yuasa S, Narimatsu H. *Glycobiology*. 2007; 17:1–9. [PubMed: 16973732]
23. Muramatsu T. *J Biochem*. 2000; 127:171–176. [PubMed: 10731680]
24. Stickens D, Zak BM, Rougier N, Esko JD, Werb Z. *Development*. 2005; 132:5055–5068. [PubMed: 16236767]
25. Di Rocco M, Hennet T, Grubenmann CE, Pagliardini S, Allegri AEM, Frank CG, Aebi M, Vignola S, Jaeken J. *J Inherited Metab Dis*. 2005; 28:1162–1164. [PubMed: 16435218]
26. Endo T, Toda T. *Biol Pharm Bull*. 2003; 26:1641–1647. [PubMed: 14646163]
27. Lowe JB, Marth JD. *Annu Rev Biochem*. 2003; 72:643–691. [PubMed: 12676797]
28. Marquardt T, Denecke J. *Eur J Pediatr*. 2003; 162:359–379. [PubMed: 12756558]
29. Schachter H. *Cell Mol Life Sci*. 2001; 58:1085–1104. [PubMed: 11529501]

30. Varki NM, Varki A. *Lab Invest.* 2007; 87:851–857. [PubMed: 17632542]
31. Sato C. *Trends Glycosci Glycotechnol.* 2004; 16:331–344.
32. Angata T, Varki A. *Chem Rev.* 2002; 102:439–469. [PubMed: 11841250]
33. Edelman GM. *Annu Rev Cell Biol.* 1986; 2:81–116. [PubMed: 3548776]
34. Rutishauser U, Landmesser L. *Trends Neurosci.* 1996; 19:422–427. [PubMed: 8888519]
35. Malykh YN, Schauer R, Shaw L. *Biochimie.* 2001; 83:623–634. [PubMed: 11522391]
36. Bast RC, Bates S, Bredt AB, Desch CE, Fritsche H, Fues L, Hayes DF, Kemeny NE, Kragen M, Jessup J, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Smith TJ, Taube S, Winn RJ. *J Clin Oncol.* 1996; 14:2843–2877. [PubMed: 8874347]
37. Ajioka Y, Allison LJ, Jass JR. *J Clin Pathol.* 1996; 49:560–564. [PubMed: 8813954]
38. Kalela A, Ponnio M, Koivu TA, Hoyhtya M, Huhtala H, Sillanaukee P, Nikkari ST. *Eur J Clin Invest.* 2000; 30:99–104. [PubMed: 10651833]
39. Crocker PR, Hartnell A, Munday J, Nath D. *Glycoconjugate J.* 1997; 14:601–609.
40. Corfield AP, Williams AJK, Clamp JR, Wagner SA, Mountford RA. *Clin Sci.* 1988; 74:71–78. [PubMed: 3338253]
41. Gee GV, Dugan AS, Tsomaia N, Mierke DF, Atwood WJ. *Glycoconjugate J.* 2006; 23:19–26.
42. Alexander DA, Dimock K. *J Virol.* 2002; 76:11265–11272. [PubMed: 12388686]
43. Ciarlet M, Crawford SE, Estes MK. *J Virol.* 2001; 75:11834–11850. [PubMed: 11689665]
44. Huberman K, Peluso RW, Moscona A. *Virology.* 1995; 214:294–300. [PubMed: 8525632]
45. Crocker PR, Paulson JC, Varki A. *Nat Rev Immunol.* 2007; 7:255–266. [PubMed: 17380156]
46. Trapp BD. *Ann NY Acad Sci.* 1990; 605:29–43. [PubMed: 1702602]
47. Kelm S, Pelz A, Schauer R, Filbin MT, Tang S, Debellard ME, Schnaar RL, Mahoney JA, Hartnell A, Bradfield P, Crocker PR. *Curr Biol.* 1994; 4:965–972. [PubMed: 7533044]
48. Schachner M, Bartsch U. *Glia.* 2000; 29:154–165. [PubMed: 10625334]
49. DeBellard ME, Tang S, Mukhopadhyay G, Shen YJ, Filbin MT. *Mol Cell Neurosci.* 1996; 7:89–101. [PubMed: 8731478]
50. Filbin MT. *Curr Opin Neurobiol.* 1995; 5:588–595. [PubMed: 8580710]
51. Mukhopadhyay G, Doherty P, Walsh FS, Crocker PR, Filbin MT. *Neuron.* 1994; 13:757–767. [PubMed: 7522484]
52. Montag D, Giese KP, Bartsch U, Martini R, Lang Y, Bluthmann H, Karthigasan J, Kirschner DA, Wintergerst ES, Nave KA, Zielasek J, Toyka KV, Lipp HP, Schachner M. *Neuron.* 1994; 13:229–246. [PubMed: 7519026]
53. Li CM, Tropak MB, Gerlai R, Clapoff S, Abramownewerly W, Trapp B, Peterson A, Roder J. *Nature.* 1994; 369:747–750. [PubMed: 7516497]
54. Crocker PR, Kelm S, Hartnell A, Freeman S, Nath D, Vinson M, Mucklow S. *Biochem Soc Trans.* 1996; 24:150–156. [PubMed: 8674645]
55. Vyas AA, Patel HV, Fromholt SE, Heffer-Laue M, Vyas KA, Dang JY, Schachner M, Schnaar RL. *Proc Natl Acad Sci USA.* 2002; 99:8412–8417. [PubMed: 12060784]
56. Yang LJS, Zeller CB, Shaper NL, Kiso M, Hasegawa A, Shapiro RE, Schnaar RL. *Proc Natl Acad Sci USA.* 1996; 93:814–818. [PubMed: 8570640]
57. Collins BE, Kiso M, Hasegawa A, Tropak MB, Roder JC, Crocker PR, Schnaar RL. *J Biol Chem.* 1997; 272:16889–16895. [PubMed: 9201997]
58. Sheikh KA, Sun J, Liu YJ, Kawai H, Crawford TO, Proia RL, Griffin JW, Schnaar RL. *Proc Natl Acad Sci USA.* 1999; 96:7532–7537. [PubMed: 10377449]
59. Chiavegatto S, Sun J, Nelson RJ, Schnaar RL. *Exp Neurol.* 2000; 166:227–234. [PubMed: 11085888]
60. Cremer H, Lange R, Christoph A, Plomann M, Vopper G, Roes J, Brown R, Baldwin S, Kraemer P, Scheff S, Barthels D, Rajewsky K, Wille W. *Nature.* 1994; 367:455–459. [PubMed: 8107803]
61. Tomasiewicz H, Ono K, Yee DL, Thompson C, Goridis C, Rutishauser U, Magnuson T. *Neuron.* 1993; 11:1163–1174. [PubMed: 8274281]
62. Acheson A, Sunshine JL, Rutishauser U. *J Cell Biol.* 1991; 114:143–153. [PubMed: 2050739]

63. Bruses JL, Rutishauser U. *Biochimie*. 2001; 83:635–643. [PubMed: 11522392]
64. Cremer H, Chazal G, Lledo PM, Rougon G, Montaron MF, Mayo W, Le Moal M, Abrous DN. *Int J Dev Neurosci*. 2000; 18:213–220. [PubMed: 10715576]
65. Cremer H, Chazal G, Carleton A, Goridis C, Vincent JD, Lledo PM. *Proc Natl Acad Sci USA*. 1998; 95:13242–13247. [PubMed: 9789073]
66. Seki T, Rutishauser U. *J Neurosci*. 1998; 18:3757–3766. [PubMed: 9570806]
67. Cremer H, Chazal G, Goridis C, Represa A. *Mol Cell Neurosci*. 1997; 8:323–335. [PubMed: 9073395]
68. Muller D, Wang C, Skibo G, Toni N, Cremer H, Calaora V, Rougon G, Kiss JZ. *Neuron*. 1996; 17:413–422. [PubMed: 8816705]
69. Becker CG, Artola A, GerardySchahn R, Decker T, Welzl H, Schachner M. *J Neurosci Res*. 1996; 45:143–152. [PubMed: 8843031]
70. Hu HY, Tomasiewicz H, Magnuson T, Rutishauser U. *Neuron*. 1996; 16:735–743. [PubMed: 8607992]
71. Uryu K, Butler AK, Chesselet MF. *J Comp Neurol*. 1999; 405:216–232. [PubMed: 10023811]
72. Butler AK, Uryu K, Chesselet MF. *Dev Neurosci*. 1998; 20:253–262. [PubMed: 9691199]
73. Wood GK, Liang JJ, Flores G, Sultan A, Quirion R, Srivastava LK. *Mol Brain Res*. 1997; 51:69–81. [PubMed: 9427508]
74. Seki T, Arai Y. *Neurosci Res*. 1993; 17:265–290. [PubMed: 8264989]
75. Kuhn HG, DickinsonAnson H, Gage FH. *J Neurosci*. 1996; 16:2027–2033. [PubMed: 8604047]
76. Alonso G, Prieto M, Legrand A, Chauvet N. *J Comp Neurol*. 1997; 384:181–199. [PubMed: 9215717]
77. Theodosis DT, Rougon G, Poulain DA. *Proc Natl Acad Sci USA*. 1991; 88:5494–5498. [PubMed: 2062831]
78. Yang PF, Yin XH, Rutishauser U. *J Cell Biol*. 1992; 116:1487–1496. [PubMed: 1541638]
79. Dityatev A, Dityateva G, Sytnyk V, Delling M, Toni N, Nikonenko I, Muller D, Schachner M. *J Neurosci*. 2004; 24:9372–9382. [PubMed: 15496673]
80. Vawter MP, Usen N, Thatcher L, Ladenheim B, Zhang PS, VanderPutten DM, Conant K, Herman MM, van Kammen DP, Sedvall G, Garver DL, Freed WJ. *Exp Neurol*. 2001; 172:29–46. [PubMed: 11681838]
81. Vawter MP. *Eur J Pharmacol*. 2000; 405:385–395. [PubMed: 11033343]
82. Barbeau D, Liang JJ, Robitaille Y, Quirion R, Srivastava LK. *Proc Natl Acad Sci USA*. 1995; 92:2785–2789. [PubMed: 7708724]
83. Mikkonen M, Soinen H, Tapiola T, Alafuzoff I, Miettinen R. *Eur J Neurosci*. 1999; 11:1754–1764. [PubMed: 10215928]
84. Nakanishi S. *Neuron*. 1994; 13:1031–1037. [PubMed: 7946343]
85. Hammond MSL, Sims C, Parameshwaran K, Suppiramaniam V, Schachner M, Dityatev A. *J Biol Chem*. 2006; 281:34859–34869. [PubMed: 16987814]
86. Kelm S, Brossmer R, Isecke R, Gross HJ, Strenge K, Schauer R. *Eur J Biochem*. 1998; 255:663–672. [PubMed: 9738906]
87. Strenge K, Schauer R, Bovin N, Hasegawa A, Ishida H, Kiso M, Kelm S. *Eur J Biochem*. 1998; 258:677–685. [PubMed: 9874234]
88. May AP, Robinson RC, Vinson M, Crocker PR, Jones EY. *Mol Cell*. 1998; 1:719–728. [PubMed: 9660955]
89. Blixt O, Collins BE, van den Nieuwenhof IM, Crocker PR, Paulson JC. *J Biol Chem*. 2003; 278:31007–31019. [PubMed: 12773526]
90. Vyas AA, Blixt O, Paulson JC, Schnaar RL. *J Biol Chem*. 2005; 280:16305–16310. [PubMed: 15701648]
91. Shelke SV, Gao GP, Mesch S, Gathje H, Kelm S, Schwardt O, Ernst B. *Bioorg Med Chem*. 2007; 15:4951–4965. [PubMed: 17507233]
92. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. *Adv Drug Delivery Rev*. 1997; 23:3–25.

93. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. *J Med Chem.* 2002; 45:2615–2623. [PubMed: 12036371]
94. Zhang Y, Zhang XY, Wu DS, Verhaagen J, Richardson PM, Yeh J, Bo XN. *Mol Ther.* 2007; 15:1796–1804. [PubMed: 17551503]
95. Papastefanaki F, Chen P, Lavdas AA, Thornaidou D, Schachner M, Matsas R. *Brain.* 2007; 130:2159–2174. [PubMed: 17626035]
96. Brisson JR, Baumann H, Imberty A, Perez S, Jennings HJ. *Biochemistry.* 1992; 31:4996–5004. [PubMed: 1376145]
97. Toikka J, Aalto J, Hayrinen J, Pelliniemi LJ, Finne J. *J Biol Chem.* 1998; 273:28557–28559. [PubMed: 9786844]
98. Torregrossa P, Buhl L, Bancila M, Durbec P, Schafer C, Schachner M, Rougon G. *J Biol Chem.* 2004; 279:30707–30714. [PubMed: 15131117]
99. Wieser JR, Heisner A, Stehling P, Oesch F, Reutter W. *FEBS Lett.* 1996; 395:170–173. [PubMed: 8898088]
100. Kayser H, Ats C, Lehmann J, Reutter W. *Experientia.* 1993; 49:885–887. [PubMed: 8224106]
101. Kayser H, Geilen CC, Paul C, Zeitler R, Reutter W. *FEBS Lett.* 1992; 301:137–140. [PubMed: 1568471]
102. Kayser H, Zeitler R, Hoppe B, Reutter W. *J Labelled Compd Radiopharm.* 1992; 31:711–715.
103. Kayser H, Zeitler R, Kannicht C, Grunow D, Nuck R, Reutter W. *J Biol Chem.* 1992; 267:16934–16938. [PubMed: 1512235]
104. Fitz W, Wong CH. *J Org Chem.* 1994; 59:8279–8280.
105. Kosa RE, Gross HJ. *Biochem Biophys Res Commun.* 1993; 190:914–920. [PubMed: 8439340]
106. Sparks MA, Williams KW, Lukacs C, Schrell A, Priebe G, Spaltenstein A, Whitesides GM. *Tetrahedron.* 1993; 49:1–12.
107. Schmidt C, Stehling P, Schnitzer J, Reutter W, Horstkorte R. *J Biol Chem.* 1998; 273:19146–19152. [PubMed: 9668100]
108. Câmara J, French-Constant C. *J Neurol.* 2007; 254(Suppl 1):I15–I22.
109. Cudrici C, Niculescu T, Niculescu F, Shin ML, Rus H. *J Rehab Res Dev.* 2006; 43:123–131.
110. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. *Brain.* 1999; 122:2279–2295. [PubMed: 10581222]
111. Learish RD, Brustle O, Zhang SC, Duncan ID. *Ann Neurol.* 1999; 46:716–722. [PubMed: 10553988]
112. delosMonteros AE, Zhao P, Huang C, Pan T, Chang R, Nazarian R, Espejo D, deVellis J. *J Neurosci Res.* 1997; 50:872–887. [PubMed: 9418974]
113. Saito M, Kitamura H, Sugiyama K. *J Neurochem.* 2001; 78:64–74. [PubMed: 11432974]
114. Schmidt C, Ohlemeyer C, Kettenmann H, Reutter W, Horstkorte R. *FEBS Lett.* 2000; 478:276–280. [PubMed: 10930582]
115. Sweetnam P, Nestler E, Gallombardo P, Brown S, Duman R, Bracha HS, Tallman J. *Mol Brain Res.* 1987; 2:223–233.
116. Sweetnam PM, Tallman JF. *Mol Pharmacol.* 1986; 29:299–306. [PubMed: 3005837]
117. Buttner B, Kannicht C, Schmidt C, Loster K, Reutter W, Lee HY, Nohring S, Horstkorte R. *J Neurosci.* 2002; 22:8869–8875. [PubMed: 12388593]
118. Charter NW, Mahal LK, Koshland DE, Bertozzi CR. *J Biol Chem.* 2002; 277:9255–9261. [PubMed: 11786551]
119. Couve A, Kittler JT, Uren JM, Calver AR, Pangalos MN, Walsh FS, Moss SJ. *Mol Cell Neurosci.* 2001; 17:317–328. [PubMed: 11178869]
120. Gao LY, Gu XB, Yu DS, Yu RK, Zeng GC. *Biochem Biophys Res Commun.* 1996; 224:103–107. [PubMed: 8694795]
121. Mahal LK, Charter NW, Angata K, Fukuda M, Koshland DE, Bertozzi CR. *Science.* 2001; 294:380–382. [PubMed: 11598302]
122. Pon RA, Lussier M, Yang QL, Jennings HJ. *J Exp Med.* 1997; 185:1929–1938. [PubMed: 9166422]

123. Pon RA, Biggs NJ, Jennings HJ. *Glycobiology*. 2007; 17:249–260. [PubMed: 17172262]
124. Horstkorte R, Muhlenhoff M, Reutter W, Nohring S, Zimmermann-Kordmann M, Gerardy-Schahn R. *Exp Cell Res*. 2004; 298:268–274. [PubMed: 15242781]
125. Collins BE, Fralich TJ, Itonori S, Ichikawa Y, Schnaar RL. *Glycobiology*. 2000; 10:11–20. [PubMed: 10570219]
126. Chou HH, Takematsu H, Diaz S, Iber J, Nickerson E, Wright KL, Muchmore EA, Nelson DL, Warren ST, Varki A. *Proc Natl Acad Sci USA*. 1998; 95:11751–11756. [PubMed: 9751737]
127. Collins BE, Yang LJS, Mukhopadhyay G, Filbin MT, Kiso M, Hasegawa A, Schnaar RL. *J Biol Chem*. 1997; 272:1248–1255. [PubMed: 8995428]
128. Mahal LK, Bertozzi CR. *Chem Biol*. 1997; 4:415–422. [PubMed: 9224572]
129. Mahal LK, Yarema KJ, Bertozzi CR. *Science*. 1997; 276:1125–1128. [PubMed: 9173543]
130. Dube DH, Bertozzi CR. *Curr Opin Chem Biol*. 2003; 7:616–625. [PubMed: 14580567]
131. Jacobs, CL.; Yarema, KJ.; Mahal, LK.; Nauman, DA.; Charters, NW.; Bertozzi, CR. Applications of Chimeric Genes and Hybrid Proteins Part B, Cell Biology and Physiology. In: Thorner, J.; Emr, SD.; Abelson, JN., editors. *Methods in Enzymology*. Academic Press; San Diego, CA: 2000. p. 327
132. Charter NW, Mahal LK, Koshland DE, Bertozzi CR. *Glycobiology*. 2000; 10:1049–1056. [PubMed: 11030751]
133. Moloney DJ, Shair LH, Lu FM, Xia J, Locke R, Matta KL, Haltiwanger RS. *J Biol Chem*. 2000; 275:9604–9611. [PubMed: 10734111]
134. Kelly RJ, Rouquier S, Giorgi D, Lennon GG, Lowe JB. *J Biol Chem*. 1995; 270:4640–4649. [PubMed: 7876235]
135. Larsen RD, Ernst LK, Nair RP, Lowe JB. *Proc Natl Acad Sci USA*. 1990; 87:6674–6678. [PubMed: 2118655]
136. Lowe JB. *Baillieres Clin Haematol*. 1993; 6:465–492. [PubMed: 8043935]
137. Jork R, Smalla KH, Karsten U, Grecksch G, Ruthrich HL, Matthies H. *Neurosci Res Commun*. 1991; 8:21–27.
138. Rose SPR, Jork R. *Behav Neural Biol*. 1987; 48:246–258. [PubMed: 3675519]
139. Kaneko M, Kudo T, Iwasaki H, Ikehara Y, Nishihara S, Nakagawa S, Sasaki K, Shiina T, Inoko H, Saitou N, Narimatsu H. *FEBS Lett*. 1999; 452:237–242. [PubMed: 10386598]
140. Natsuka S, Lowe JB. *Curr Opin Struct Biol*. 1994; 4:683–691.
141. Miyoshi E, Noda K, Yamaguchi Y, Inoue S, Ikeda Y, Wang WG, Ko JH, Uozumi N, Li W, Taniguchi N. *Biochim Biophys Acta*. 1999; 1473:9–20. [PubMed: 10580126]
142. Nishihara S, Iwasaki H, Kaneko M, Tawada A, Ito M, Narimatsu H. *FEBS Lett*. 1999; 462:289–294. [PubMed: 10622713]
143. Luo Y, Koles K, Vorndam W, Haltiwanger RS, Panin VM. *J Biol Chem*. 2006; 281:9393–9399. [PubMed: 16464857]
144. Wang Y, Shao L, Shi SL, Harris RJ, Spellman MW, Stanley P, Haltiwanger RS. *J Biol Chem*. 2001; 276:40338–40345. [PubMed: 11524432]
145. Springer TA. *Cell*. 1994; 76:301–314. [PubMed: 7507411]
146. Lowe JB. *Kidney Int*. 1997; 51:1418–1426. [PubMed: 9150453]
147. Hooper LV, Gordon JI. *Glycobiology*. 2001; 11:1R–10R. [PubMed: 11181556]
148. Guruge JL, Falk PG, Lorenz RG, Dans M, Wirth HP, Blaser MJ, Berg DE, Gordon JI. *Proc Natl Acad Sci USA*. 1998; 95:3925–3930. [PubMed: 9520469]
149. Li YX, Li L, Irvine KD, Baker NE. *Development*. 2003; 130:2829–2840. [PubMed: 12756168]
150. Sasamura T, Sasaki N, Miyashita F, Nakao S, Ishikawa HO, Ito M, Kitagawa M, Harigaya K, Spana E, Bilder D, Perrimon N, Matsuno K. *Development*. 2003; 130:4785–4795. [PubMed: 12917292]
151. Block TM, Comunale MA, Lowman M, Steel LF, Romano PR, Fimmel C, Tennant BC, London WT, Evans AA, Blumberg BS, Dwek RA, Mattu TS, Mehta AS. *Proc Natl Acad Sci USA*. 2005; 102:779–784. [PubMed: 15642945]

152. Wang JW, Ambros RA, Weber PB, Rosano TG. *Cancer Res.* 1995; 55:3654–3658. [PubMed: 7627975]
153. Yazawa S, Nakamura J, Asao T, Nagamachi Y, Sagi M, Matta KL, Tachikawa T, Akamatsu M. *Jpn J Cancer Res.* 1993; 84:989–995. [PubMed: 8407568]
154. Thompson S, Dargan E, Turner GA. *Cancer Lett.* 1992; 66:43–48. [PubMed: 1451094]
155. Lowe JB. *Curr Opin Cell Biol.* 2003; 15:531–538. [PubMed: 14519387]
156. Vestweber D, Blanks JE. *Physiol Rev.* 1999; 79:181–213. [PubMed: 9922371]
157. Butcher EC, Picker LJ. *Science.* 1996; 272:60–66. [PubMed: 8600538]
158. Listinsky JJ, Siegal GP, Listinsky CM. *Am J Clin Pathol.* 1998; 110:425–440. [PubMed: 9763028]
159. Macartney JC. *J Pathol.* 1987; 152:23–30. [PubMed: 3625392]
160. Kim YJ, Borsig L, Varki NM, Varki A. *Proc Natl Acad Sci USA.* 1998; 95:9325–9330. [PubMed: 9689079]
161. Orntoft TF, Vestergaard EM. *Electrophoresis.* 1999; 20:362–371. [PubMed: 10197444]
162. Kim YJ, Varki A. *Glycoconjugate J.* 1997; 14:569–576.
163. Miyake M, Taki T, Hitomi S, Hakomori S. *N Engl J Med.* 1992; 327:14–18. [PubMed: 1317941]
164. Yakubenia S, Wild MK. *FEBS J.* 2006; 273:4390–4398. [PubMed: 16956371]
165. Artavanis-Tsakonas S, Rand MD, Lake RJ. *Science.* 1999; 284:770–776. [PubMed: 10221902]
166. Rampal R, Arboleda-Velasquez JF, Nita-Lazar A, Kosik KS, Haltiwanger RS. *J Biol Chem.* 2005; 280:32133–32140. [PubMed: 15994302]
167. Lei L, Xu AG, Panin VM, Irvine KD. *Development.* 2003; 130:6411–6421. [PubMed: 14627724]
168. Haines N, Irvine KD. *Nat Rev Mol Cell Biol.* 2003; 4:786–797. [PubMed: 14570055]
169. Okajima T, Irvine KD. *Cell.* 2002; 111:893–904. [PubMed: 12526814]
170. Louvi A, Artavanis-Tsakonas S. *Nat Rev Neurosci.* 2006; 7:93–102. [PubMed: 16429119]
171. Lu, LC.; Stanley, P. Functional Glycomics. In: Fukuda, M., editor. *Methods in Enzymology.* Vol. 417. Elsevier; Amsterdam: 2006.
172. Shi SL, Stanley P. *Proc Natl Acad Sci USA.* 2003; 100:5234–5239. [PubMed: 12697902]
173. Sukumar R, Rose SPR, Burgoyne RD. *J Neurochem.* 1980; 34:1000–1006. [PubMed: 7359125]
174. McCabe NR, Rose SPR. *Neurochem Res.* 1985; 10:1083–1095. [PubMed: 4058654]
175. Pohle W, Acosta L, Ruthrich H, Krug M, Matthies H. *Brain Res.* 1987; 410:245–256. [PubMed: 3594237]
176. Bullock S, Rose SPR, Zamani R. *J Neurochem.* 1992; 58:2145–2154. [PubMed: 1573396]
177. Krug M, Wagner M, Staak S, Smalla KH. *Brain Res.* 1994; 643:130–135. [PubMed: 7518325]
178. Matthies H, Staak S, Krug M. *Brain Res.* 1996; 725:276–280. [PubMed: 8836537]
179. Zanetta JP, Reeber A, Vincendon G, Gombos G. *Brain Res.* 1977; 138:317–328. [PubMed: 589479]
180. Krusius T, Finne J. *Eur J Biochem.* 1977; 78:369–379. [PubMed: 913404]
181. Taniguchi T, Adler AJ, Mizuochi T, Kochibe N, Kobata A. *J Biol Chem.* 1986; 261:1730–1736. [PubMed: 3944106]
182. Matsui Y, Lombard D, Massarelli R, Mandel P, Dreyfus H. *J Neurochem.* 1986; 46:144–150. [PubMed: 3940275]
183. Popov N, Schmidt S, Schulzeck S, Jork R, Lossner B, Matthies H. *Pharmacol, Biochem Behav.* 1983; 19:43–47. [PubMed: 6312462]
184. Gardiol A, Racca C, Triller A. *J Neurosci.* 1999; 19:168–179. [PubMed: 9870948]
185. Torre ER, Sterward O. *J Neurosci.* 1996; 16:5967–5978. [PubMed: 8815879]
186. Bullock S, Potter J, Rose SPR. *J Neurochem.* 1990; 54:135–142. [PubMed: 2403432]
187. Lorenzini CGA, Baldi E, Bucherelli C, Sacchetti B, Tassoni G. *Neurobiol Learn Mem.* 1997; 68:317–324. [PubMed: 9398591]
188. Matthies H, Staak S, Krug M. *Brain Res.* 1996; 725:276–280. [PubMed: 8836537]
189. Krug M, Jork R, Reymann K, Wagner M, Matthies H. *Brain Res.* 1991; 540:237–242. [PubMed: 2054616]

190. Karsten U, Pilgrim G, Hanisch FG, Uhlenbruck G, Kasper M, Stosiek P, Papsdorf G, Pasternak G. *Br J Cancer*. 1988; 58:176–181. [PubMed: 2458750]
191. Hilfiker S, Pieribone VA, Czernik AJ, Kao HT, Augustine GJ, Greengard P. *Philos Trans R Soc*. 1999; 354:269–279.
192. Ferreira A, Li L, Chin LS, Greengard P, Kosik KS. *Mol Cell Neurosci*. 1996; 8:286–299. [PubMed: 9026316]
193. Rabuka D, Hubbard SC, Laughlin ST, Argade SP, Bertozzi CR. *J Am Chem Soc*. 2006; 128:12078–12079. [PubMed: 16967952]
194. Sawa M, Hsu TL, Itoh T, Sugiyama M, Hanson SR, Vogt PK, Wong CH. *Proc Natl Acad Sci U S A*. 2006; 103:12371–12376. [PubMed: 16895981]
195. Hsu TL, Hanson SR, Kishikawa K, Wang SK, Sawa M, Wong CH. *Proc Natl Acad Sci U S A*. 2007; 104:2614–2619. [PubMed: 17296930]
196. Trachtenberg JT, Chen BE, Knott GW, Feng GP, Sanes JR, Welker E, Svoboda K. *Nature*. 2002; 420:788–794. [PubMed: 12490942]
197. Luscher C, Nicoll RA, Malenka RC, Muller D. *Nat Neurosci*. 2000; 3:545–550. [PubMed: 10816309]
198. Hanover JA. *FASEB J*. 2001; 15:1865–1876. [PubMed: 11532966]
199. Slawson C, Hart GW. *Curr Opin Struct Biol*. 2003; 13:631–636. [PubMed: 14568619]
200. Hart GW, Housley MP, Slawson C. *Nature*. 2007; 446:1017–1022. [PubMed: 17460662]
201. Slawson C, Housley MP, Hart GW. *J Cell Biochem*. 2006; 97:71–83. [PubMed: 16237703]
202. Khidekel N, Ficarro SB, Peters EC, Hsieh-Wilson LC. *Proc Natl Acad Sci USA*. 2004; 101:13132–13137. [PubMed: 15340146]
203. Comer FI, Hart GW. *Biochim Biophys Acta*. 1999; 1473:161–171. [PubMed: 10580136]
204. Wells L, Hart GW. *FEBS Lett*. 2003; 546:154–158. [PubMed: 12829252]
205. Wells L, Whalen SA, Hart GW. *Biochem Biophys Res Commun*. 2003; 302:435–441. [PubMed: 12615051]
206. Zachara NE, O'Donnell N, Cheung WD, Mercer JJ, Marth JD, Hart GW. *J Biol Chem*. 2004; 279:30133–30142. [PubMed: 15138254]
207. Wells L, Vosseller K, Hart GW. *Cell Mol Life Sci*. 2003; 60:222–228. [PubMed: 12678487]
208. Zachara NE, Hart GW. *Biochim Biophys Acta*. 2004; 1673:13–28. [PubMed: 15238246]
209. Fulop N, Marchase RB, Chatham JC. *Cardiovasc Res*. 2007; 73:288–297. [PubMed: 16970929]
210. Parker GJ, Lund KC, Taylor RP, McClain DA. *J Biol Chem*. 2003; 278:10022–10027. [PubMed: 12510058]
211. Dias WB, Hart GW. *Mol Biosyst*. 2007; 3:766–772. [PubMed: 17940659]
212. Arnold CS, Hart GW. *Trends Glycosci Glycotechnol*. 1999; 11:355–370.
213. Yao PJ, Coleman PD. *Neurosci Lett*. 1998; 252:33–36. [PubMed: 9756352]
214. Yao PJ, Coleman PD. *J Neurosci*. 1998; 18:2399–2411. [PubMed: 9502801]
215. Griffith LS, Schmitz B. *Biochem Biophys Res Commun*. 1995; 213:424–431. [PubMed: 7646495]
216. Ballatore C, Lee VMY, Trojanowski JQ. *Nat Rev Neurosci*. 2007; 8:663–672. [PubMed: 17684513]
217. Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX. *Proc Natl Acad Sci USA*. 2004; 101:10804–10809. [PubMed: 15249677]
218. Robertson LA, Moya KL, Breen KC. *J Alzheimer's Dis*. 2004; 6:489–495. [PubMed: 15505370]
219. Iyer SPN, Hart GW. *Biochemistry*. 2003; 42:2493–2499. [PubMed: 12614143]
220. Cole RN, Hart GW. *J Neurochem*. 2001; 79:1080–1089. [PubMed: 11739622]
221. Shafi R, Iyer SPN, Ellies LG, O'Donnell N, Marek KW, Chui D, Hart GW, Marth JD. *Proc Natl Acad Sci USA*. 2000; 97:5735–5739. [PubMed: 10801981]
222. O'Donnell N, Zachara NE, Hart GW, Marth JD. *Mol Cell Biol*. 2004; 24:1680–1690. [PubMed: 14749383]

223. Khidekel N, Ficarro SB, Clark PM, Bryan MC, Swaney DL, Rexach JE, Sun YE, Coon JJ, Peters EC, Hsieh-Wilson LC. *Nat Chem Biol.* 2007; 3:339–348. [PubMed: 17496889]
224. Vosseller K, Trinidad JC, Chalkley RJ, Specht CG, Thalhammer A, Lynn AJ, Snedecor JO, Guan S, Medzihradzky KF, Maltby DA, Schoepfer R, Burlingame AL. *Mol Cell Proteomics.* 2006; 5:923–34. [PubMed: 16452088]
225. Cole RN, Hart GW. *J Neurochem.* 1999; 73:418–428. [PubMed: 10386995]
226. Luthi T, Haltiwanger RS, Greengard P, Bahler M. *J Neurochem.* 1991; 56:1493–1498. [PubMed: 1901592]
227. Arnold CS, Johnson GVW, Cole RN, Dong DLY, Lee M, Hart GW. *J Biol Chem.* 1996; 271:28741–28744. [PubMed: 8910513]
228. Roquemore EP, Chou TY, Hart GW. *Methods Enzymol.* 1994; 230:443–460. [PubMed: 8139512]
229. Comer FI, Vosseller K, Wells L, Accavitti MA, Hart GW. *Anal Biochem.* 2001; 293:169–177. [PubMed: 11399029]
230. Snow CM, Senior A, Gerace L. *J Cell Biol.* 1987; 104:1143–1156. [PubMed: 2437126]
231. Khidekel N, Arndt S, Lamarre-Vincent N, Lippert A, Poulin-Kerstien KG, Ramakrishnan B, Qasba PK, Hsieh-Wilson LC. *J Am Chem Soc.* 2003; 125:16162–16163. [PubMed: 14692737]
232. Ramakrishnan B, Qasba PK. *J Biol Chem.* 2002; 277:20833–20839. [PubMed: 11916963]
233. Tai HC, Khidekel N, Ficarro SB, Peters EC, Hsieh-Wilson LC. *J Am Chem Soc.* 2004; 126:10500–10501. [PubMed: 15327282]
234. Deller T, Korte M, Chabanis S, Drakew A, Schwegler H, Stefani GG, Zuniga A, Schwarz K, Bonhoeffer T, Zeller R, Frotscher M, Mundel P. *Proc Natl Acad Sci USA.* 2003; 100:10494–10499. [PubMed: 12928494]
235. Vazquez LE, Chen HJ, Sokolova I, Knuesel I, Kennedy MB. *J Neurosci.* 2004; 24:8862–8872. [PubMed: 15470153]
236. Sala C, Piech V, Wilson NR, Passafaro M, Liu GS, Sheng M. *Neuron.* 2001; 31:115–130. [PubMed: 11498055]
237. Israely I, Costa RM, Xie CW, Silva AJ, Kosik KS, Liu X. *Curr Biol.* 2004; 14:1657–1663. [PubMed: 15380068]
238. Zhang M, Wang W. *Acc Chem Res.* 2003; 36:530–538. [PubMed: 12859214]
239. Hsieh-Wilson, LC.; Khidekel, N.; Arndt, SE.; Tai, H-C. Method and compositions for the detection of protein glycosylation. U.S. Patent Application 20050130235. 2005.
240. Clark PM, Dweck JF, Mason DE, Hart C, Peters EC, Agnew BJ, Hsieh-Wilson LC. Unpublished results.
241. Voadlo DJ, Hang HC, Kim EJ, Hanover JA, Bertozzi CR. *Proc Natl Acad Sci USA.* 2003; 100:9116–9121. [PubMed: 12874386]
242. Lubas WA, Smith M, Starr CM, Hanover JA. *Biochemistry.* 1995; 34:1686–1694. [PubMed: 7849028]
243. Nandi A, Sprung R, Barma DK, Zhao YX, Kim SC, Falck JR, Zhao YM. *Anal Chem.* 2006; 78:452–458. [PubMed: 16408927]
244. Sprung R, Nandi A, Chen Y, Kim SC, Barma D, Falck JR, Zhao YM. *J Proteome Res.* 2005; 4:950–957. [PubMed: 15952742]
245. Dube DH, Prescher JA, Quang CN, Bertozzi CR. *Proc Natl Acad Sci USA.* 2006; 103:4819–4824. [PubMed: 16549800]
246. Wells L, Vosseller K, Cole RN, Cronshaw JM, Matunis MJ, Hart GW. *Mol Cell Proteomics.* 2002; 1:791–804. [PubMed: 12438562]
247. Downs F, Herp A, Moschera J, Pigman W. *Biochim Biophys Acta.* 1973; 328:182–192. [PubMed: 4796927]
248. Bertolini M, Pigman W. *J Biol Chem.* 1967; 242:3776. [PubMed: 6037543]
249. Syka JEP, Coon JJ, Schroeder MJ, Shabanowitz J, Hunt DF. *Proc Natl Acad Sci USA.* 2004; 101:9528–9533. [PubMed: 15210983]
250. Golks A, Tran TTT, Goetschy JF, Guerini D. *EMBO J.* 2007; 26:4368–4379. [PubMed: 17882263]

251. Roquemore EP, Chevrier MR, Cotter RJ, Hart GW. *Biochemistry*. 1996; 35:3578–3586. [PubMed: 8639509]
252. Liu K, Paterson AJ, Chin E, Kudlow JE. *Proc Natl Acad Sci USA*. 2000; 97:2820–2825. [PubMed: 10717000]
253. Rex-Mathes M, Werner S, Strutas D, Griffith LS, Viebahn C, Thelen K, Schmitz B. *Biochimie*. 2001; 83:583–590. [PubMed: 11522386]
254. Marshall S, Bacote V, Traxinger RR. *J Biol Chem*. 1991; 266:4706–4712. [PubMed: 2002019]
255. Griffith LS, Schmitz B. *Eur J Biochem*. 1999; 262:824–831. [PubMed: 10411645]
256. Buse MG. *Am J Phys-Endocrinol Metab*. 2006; 290:E1–E8.
257. McClain DA, Lubas WA, Cooksey RC, Hazel M, Parker GJ, Love DC, Hanover JA. *Proc Natl Acad Sci USA*. 2002; 99:10695–10699. [PubMed: 12136128]
258. Carrillo LD, Krishnamoorthy L, Mahal LK. *J Am Chem Soc*. 2006; 128:14768–14769. [PubMed: 17105262]
259. Thiel G, Cibelli G. *J Cell Physiol*. 2002; 193:287–292. [PubMed: 12384981]
260. Jones MW, Errington ML, French PJ, Fine A, Bliss TVP, Garel S, Charnay P, Bozon B, Laroche S, Davis S. *Nat Neurosci*. 2001; 4:289–296. [PubMed: 11224546]
261. Ong SE, Mittler G, Mann M. *Nat Methods*. 2004; 1:119–126. [PubMed: 15782174]
262. Wang Z, Pandey A, Hart GW. *Mol Cell Proteomics*. 2007; 6:1365–1379. [PubMed: 17507370]
263. Gould TD, Manji HK. *Neuropsychopharmacology*. 2005; 30:1223–1237. [PubMed: 15827567]
264. Doble BW, Woodgett JR. *J Cell Sci*. 2003; 116:1175–1186. [PubMed: 12615961]
265. Lee TN, Alborn WE, Knierman MD, Konrad RJ. *Biochem Biophys Res Commun*. 2006; 350:1038–1043. [PubMed: 17045574]
266. Meglasson MD, Burch PT, Berner DK, Najafi H, Matschinsky FM. *Diabetes*. 1986; 35:1163–1173. [PubMed: 3530846]
267. Szkudelski T. *Physiol Res*. 2001; 50:537–546. [PubMed: 11829314]
268. Gross BJ, Kraybill BC, Walker S. *J Am Chem Soc*. 2005; 127:14588–14589. [PubMed: 16231908]
269. Kim EJ, Perreira M, Thomas CJ, Hanover JA. *J Am Chem Soc*. 2006; 128:4234–4235. [PubMed: 16568991]
270. Stubbs KA, Zhang N, Vocadlo DJ. *Org Biomol Chem*. 2006; 4:839–845. [PubMed: 16493467]
271. Dorfmueller HC, Borodkin VS, Schimpl M, Shepherd SM, Shpiro NA, van Aalten DMF. *J Am Chem Soc*. 2006; 128:16484–16485. [PubMed: 17177381]
272. Knapp S, Abdo M, Ajayi K, Huhn RA, Emge TJ, Kim EJ, Hanover JA. *Org Lett*. 2007; 9:2321–2324. [PubMed: 17508759]
273. Macauley MS, Whitworth GE, Debowski AW, Chin D, Vocadlo DJ. *J Biol Chem*. 2005; 280:25313–25322. [PubMed: 15795231]
274. Barrow RT, Parker ET, Krishnaswamy S, Lollar P. *J Biol Chem*. 1994; 269:26796–26800. [PubMed: 7929416]
275. Bourin MC, Lindahl U. *Biochem J*. 1993; 289:313–330. [PubMed: 8380990]
276. Iozzo RV. *Nat Rev Mol Cell Biol*. 2005; 6:646–656. [PubMed: 16064139]
277. Casu B, Guerrini M, Naggi A, Perez M, Torri G, Ribatti D, Carminati P, Giannini G, Penco S, Pisano C, Belleri M, Rusnati M, Presta M. *Biochemistry*. 2002; 41:10519–10528. [PubMed: 12173939]
278. Iozzo RV, San Antonio JD. *J Clin Invest*. 2001; 108:349–355. [PubMed: 11489925]
279. Liu DF, Shriver Z, Venkataraman G, El Shabrawi Y, Sasisekharan R. *Proc Natl Acad Sci USA*. 2002; 99:568–573. [PubMed: 11805315]
280. Lokeshwar VB, Rubinowicz D, Schroeder GL, Forgacs E, Minna JD, Block NL, Nadji M, Lokeshwar BL. *J Biol Chem*. 2001; 276:11922–11932. [PubMed: 11278412]
281. Denholm EM, Lin YQ, Silver PJ. *Eur J Pharmacol*. 2001; 416:213–221. [PubMed: 11290371]
282. Bovolenta P, Fernaud-Espinosa I. *Prog Neurobiol*. 2000; 61:113–132. [PubMed: 10704995]
283. Gama CI, Tully SE, Sotogaku N, Clark PM, Rawat M, Vaidehi N, Goddard WA, Nishi A, Hsieh-Wilson LC. *Nat Chem Biol*. 2006; 2:467–473. [PubMed: 16878128]

284. Schwartz NB, Domowicz M. *Glycoconjugate J.* 2004; 21:329–341.
285. Tully SE, Mabon R, Gama CI, Tsai SM, Liu XW, Hsieh-Wilson LC. *J Am Chem Soc.* 2004; 126:7736–7737. [PubMed: 15212495]
286. Barritt AW, Davies M, Marchand F, Hartley R, Grist J, Yip P, McMahon SB, Bradbury EJ. *J Neurosci.* 2006; 26:10856–10867. [PubMed: 17050723]
287. Yick LW, Wu WT, So KF, Yip HK, Shum DKY. *Neuroreport.* 2000; 11:1063–1067. [PubMed: 10790883]
288. Gorio A, Vergani L, Lesma E, Di Giulio AM. *J Neurosci Res.* 1998; 51:559–562. [PubMed: 9511999]
289. Hacker U, Nybakken K, Perrimon N. *Nat Rev Mol Cell Biol.* 2005; 6:530–541. [PubMed: 16072037]
290. Lin XH. *Development.* 2004; 131:6009–6021. [PubMed: 15563523]
291. Perrimon N, Bernfield M. *Nature.* 2000; 404:725–728. [PubMed: 10783877]
292. Sugahara K, Kitagawa H. *IUBMB Life.* 2002; 54:163–175. [PubMed: 12512855]
293. Silbert JE, Sugumaran G. *IUBMB Life.* 2002; 54:177–186. [PubMed: 12512856]
294. Schwartz NB. *Front Biosci.* 2000; 5:D649–D655. [PubMed: 10877997]
295. Margolis RK, Margolis RU. *Experientia.* 1993; 49:429–446. [PubMed: 8500598]
296. Sasisekharan R, Raman R, Prabhakar V. *Annu Rev Biomed Eng.* 2006; 8:181–231. [PubMed: 16834555]
297. Itano N, Kimata K. *IUBMB Life.* 2002; 54:195–199. [PubMed: 12512858]
298. Capila I, Linhardt RJ. *Angew Chem, Int Ed.* 2002; 41:391–412.
299. Schlessinger J, Plotnikov AN, Ibrahim OA, Eliseenkova AV, Yeh BK, Yayon A, Linhardt RJ, Mohammadi M. *Mol Cell.* 2000; 6:743–750. [PubMed: 11030354]
300. Millane RP, Mitra AK, Arnott S. *J Mol Biol.* 1983; 169:903–920. [PubMed: 6415288]
301. Li FC, Shetty AK, Sugahara K. *J Biol Chem.* 2007; 282:2956–2966. [PubMed: 17145750]
302. Noti C, de Paz JL, Polito L, Seeberger PH. *Chem–Eur J.* 2006; 12:8664–8686. [PubMed: 17066397]
303. Bao XF, Muramatsu T, Sugahara K. *J Biol Chem.* 2005; 280:35318–35328. [PubMed: 16120610]
304. Shipp EL, Hsieh-Wilson LC. *Chem Biol.* 2007; 14:195–208. [PubMed: 17317573]
305. Ashikari-Hada S, Habuchi H, Kariya Y, Itoh N, Reddi AH, Kimata K. *J Biol Chem.* 2004; 279:12346–12354. [PubMed: 14707131]
306. Faham S, Linhardt RJ, Rees DC. *Curr Opin Struct Biol.* 1998; 8:578–586. [PubMed: 9818261]
307. Ostrovsky O, Berman B, Gallagher J, Mulloy B, Fernig DG, Delehedde M, Ron D. *J Biol Chem.* 2002; 277:2444–2453. [PubMed: 11714710]
308. Raman R, Venkataraman G, Ernst S, Sasisekharan V, Sasisekharan R. *Proc Natl Acad Sci USA.* 2003; 100:2357–2362. [PubMed: 12604799]
309. Brickman YG, Ford MD, Gallagher JT, Nurcombe V, Bartlett PF, Turnbull JE. *J Biol Chem.* 1998; 273:4350–4359. [PubMed: 9468484]
310. Kitagawa H, Tsutsumi K, Tone Y, Sugahara K. *J Biol Chem.* 1997; 272:31377–31381. [PubMed: 9395468]
311. Fernaud-Espinosa I, Nieto-Sampedro M, Bovolenta P. *J Neuro-biol.* 1996; 30:410–424.
312. Properzi F, Carulli D, Asher RA, Muir E, Camargo LM, van Kuppevelt TH, ten Dam GB, Furukawa Y, Mikami T, Sugahara K, Toida T, Geller HM, Fawcett JW. *Eur J Neurosci.* 2005; 21:378–390. [PubMed: 15673437]
313. Liang Y, Annan RS, Carr SK, Popp S, Mevissen M, Margolis RK, Margolis RU. *J Biol Chem.* 1999; 274:17885–17892. [PubMed: 10364234]
314. Ronca F, Andersen JS, Paech V, Margolis RU. *J Biol Chem.* 2001; 276:29141–29147. [PubMed: 11375980]
315. Hu HY. *Nat Neurosci.* 2001; 4:695–701. [PubMed: 11426225]
316. Bulow HE, Hobert O. *Neuron.* 2004; 41:723–736. [PubMed: 15003172]
317. Yamaguchi Y. *Cell Mol Life Sci.* 2000; 57:276–289. [PubMed: 10766023]

318. Celio MR, Spreafico R, De Biasi S, Vitellaro-Zuccarello L. *Trends Neurosci.* 1998; 21:510–514. [PubMed: 9881847]
319. Snow DM, Mullins N, Hynds DL. *Microsc Res Technol.* 2001; 54:273–286.
320. Niederost BP, Zimmermann DR, Schwab ME, Bandtlow CE. *J Neurosci.* 1999; 19:8979–8989. [PubMed: 10516316]
321. Steinmetz MP, Horn KP, Tom VJ, Miller JH, Busch SA, Nair D, Silver DJ, Silver J. *J Neurosci.* 2005; 25:8066–8076. [PubMed: 16135764]
322. Sango K, Oohira A, Ajiki K, Tokashiki A, Horie M, Kawano H. *Exp Neurol.* 2003; 182:1–11. [PubMed: 12821372]
323. Bradbury EJ, Moon LDF, Popat RJ, King VR, Bennett GS, Patel PN, Fawcett JW, McMahon SB. *Nature.* 2002; 416:636–640. [PubMed: 11948352]
324. Moon LDF, Asher RA, Rhodes KE, Fawcett JW. *Nat Neurosci.* 2001; 4:465–466. [PubMed: 11319553]
325. Thanawiroon C, Rice KG, Toida T, Linhardt RJ. *J Biol Chem.* 2004; 279:2608–2615. [PubMed: 14610083]
326. Saad OM, Leary JA. *Anal Chem.* 2003; 75:2985–2995. [PubMed: 12964742]
327. Kinoshita A, Sugahara K. *Anal Biochem.* 1999; 269:367–378. [PubMed: 10222012]
328. Petitou M, Duchaussoy P, Driguez PA, Jaurand G, Herault JP, Lormeau JC, van Boeckel CAA, Herbert JM. *Angew Chem, Int Ed Engl.* 1998; 37:3009–3014.
329. Helmboldt A, Petitou M, Mallet JM, Herault JP, Lormeau JC, Driguez PA, Herbert JM, Sinay P. *Bioorg Med Chem Lett.* 1997; 7:1507–1510.
330. Chiba T, Jacquinet JC, Sinay P, Petitou M, Choay J. *Carbohydr Res.* 1988; 174:253–264.
331. Petitou M, Duchaussoy P, Lederman I, Choay J, Jacquinet JC, Sinay P, Torri G. *Carbohydr Res.* 1987; 167:67–75. [PubMed: 3690577]
332. Petitou M, Duchaussoy P, Lederman I, Choay J, Sinay P, Jacquinet JC, Torri G. *Carbohydr Res.* 1986; 147:221–236. [PubMed: 3708627]
333. Jacquinet JC, Petitou M, Duchaussoy P, Lederman I, Choay J, Torri G, Sinay P. *Carbohydr Res.* 1984; 130:221–241.
334. Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G. *Biochem Biophys Res Commun.* 1983; 116:492–499. [PubMed: 6651824]
335. Poletti L, Fleischer M, Vogel C, Guerrini M, Torri G, Lay L. *Eur J Org Chem.* 2001:2727–2734.
336. Van Boeckel CAA, Beetz T, Vos JN, Dejong AJM, Van Aelst SF, Van Den Bosch RH, Mertens JMR, Van Der Vlugt FA. *J Carbohydr Chem.* 1985; 4:293–321.
337. Petitou M, van Boeckel CAA. *Angew Chem, Int Ed.* 2004; 43:3118–3133.
338. Haller M, Boons GJ. *J Chem Soc, Perkin Trans 1.* 2001:814–822.
339. de Paz JL, Ojeda R, Reichardt N, Martin-Lomas M. *Eur J Org Chem.* 2003:3308–3324.
340. Orgueira HA, Bartolozzi A, Schell P, Litjens R, Palmacci ER, Seeberger PH. *Chem–Eur J.* 2003; 9:140–169. [PubMed: 12506372]
341. Lohman GJS, Seeberger PH. *J Org Chem.* 2004; 69:4081–4093. [PubMed: 15176833]
342. Angulo J, Ojeda R, de Paz JL, Lucas R, Nieto PM, Lozano RM, Redondo-Horcajo M, Gimenez-Gallego G, Martin-Lomas M. *ChemBioChem.* 2004; 5:55–61. [PubMed: 14695513]
343. Codee JDC, Stubba B, Schiattarella M, Overkleeft HS, van Boeckel CAA, van Boom JH, van der Marel GA. *J Am Chem Soc.* 2005; 127:3767–3773. [PubMed: 15771511]
344. Seeberger PH, Werz DB. *Nature.* 2007; 446:1046–1051. [PubMed: 17460666]
345. Noti C, Seeberger PH. *Chem Biol.* 2005; 12:731–756. [PubMed: 16039522]
346. Karst NA, Linhardt RJ. *Curr Med Chem.* 2003; 10:1993–2031. [PubMed: 12871100]
347. Poletti L, Lay L. *Eur J Org Chem.* 2003:2999–3024.
348. Gavard O, Hersant Y, Alais J, Duverger V, Dilhas A, Bascou A, Bonnaffe D. *Eur J Org Chem.* 2003:3603–3620.
349. Kobayashi S, Fujikawa S, Ohmae M. *J Am Chem Soc.* 2003; 125:14357–14369. [PubMed: 14624584]

350. Kobayashi S, Itoh R, Morii H, Fujikawa SI, Kimura S, Ohmae M. *J Polym Sci.* 2003; 41:3541–3548.
351. Kobayashi S, Morii H, Ito R, Ohmae M. *Macromol Symp.* 2002; 183:127–132.
352. Kobayashi S, Uyama H, Kimura S. *Chem Rev.* 2001; 101:3793–3818. [PubMed: 11740921]
353. Kobayashi S, Morii H, Itoh R, Kimura S, Ohmae M. *J Am Chem Soc.* 2001; 123:11825–11826. [PubMed: 11716751]
354. Tracy BS, Avci FY, Linhardt RJ, DeAngelis PL. *J Biol Chem.* 2007; 282:337–344. [PubMed: 17099217]
355. Kuberan B, Lech MZ, Beeler DL, Wu ZLL, Rosenberg RD. *Nat Biotechnol.* 2003; 21:1343–1346. [PubMed: 14528313]
356. Sinay P, Jacquinet JC, Petitou M, Duchaussoy P, Lederman I, Choay J, Torri G. *Carbohydr Res.* 1984; 132:C5–C9.
357. Lafont F, Prochiantz A, Valenza C, Petitou M, Pascal M, Rouget M, Rousselet A. *Dev Biol.* 1994; 165:453–468. [PubMed: 7958413]
358. Lafont F, Rouget M, Triller A, Prochiantz A, Rousselet A. *Development.* 1992; 114:17. [PubMed: 1576957]
359. Kitagawa H, Tanaka Y, Tsuchida K, Goto F, Ogawa T, Lidholt K, Lindahl U, Sugahara K. *J Biol Chem.* 1995; 270:22190–22195. [PubMed: 7673197]
360. Sugahara K, Masuda M, Harada T, Yamashina I, Dewaard P, Vliegenthart JFG. *Eur J Biochem.* 1991; 202:805–811. [PubMed: 1765094]
361. Nadanaka S, Clement A, Masayama K, Faissner A, Sugahara K. *J Biol Chem.* 1998; 273:3296–3307. [PubMed: 9452446]
362. Dou CL, Levine JM. *J Neurosci.* 1995; 15:8053–8066. [PubMed: 8613742]
363. Brittis PA, Canning DR, Silver J. *Science.* 1992; 255:733–736. [PubMed: 1738848]
364. Zhi ZL, Powell AK, Turnbull JE. *Anal Chem.* 2006; 78:4786–4793. [PubMed: 16841896]
365. Carion O, Lefebvre J, Dubreucq G, Dahri-Correia L, Correia J, Melnyk O. *ChemBioChem.* 2006; 7:817–826. [PubMed: 16550626]
366. Huang CY, Thayer DA, Chang AY, Best MD, Hoffmann J, Head S, Wong CH. *Proc Natl Acad Sci USA.* 2006; 103:15–20. [PubMed: 16373501]
367. Blixt O, Head S, Mondala T, Scanlan C, Huflejt ME, Alvarez R, Bryan MC, Fazio F, Calarese D, Stevens J, Razi N, Stevens DJ, Skehel JJ, van Die I, Burton DR, Wilson IA, Cummings R, Bovin N, Wong CH, Paulson JC. *Proc Natl Acad Sci USA.* 2004; 101:17033–17038. [PubMed: 15563589]
368. Adams EW, Ratner DM, Bokesch HR, McMahon JB, O'Keefe BR, Seeberger PH. *Chem Biol.* 2004; 11:875–881. [PubMed: 15217620]
369. Fukui S, Feizi T, Galustian C, Lawson AM, Chai WG. *Nat Biotechnol.* 2002; 20:1011–1017. [PubMed: 12219077]
370. Houseman BT, Mrksich M. *Chem Biol.* 2002; 9:443–454. [PubMed: 11983333]
371. de Paz JL, Noti C, Seeberger PH. *J Am Chem Soc.* 2006; 128:2766–2767. [PubMed: 16506732]
372. Feizi T, Fazio F, Chai W, Wong CH. *Curr Opin Struct Biol.* 2003; 13:637–645. [PubMed: 14568620]
373. Park S, Lee MR, Pyo SJ, Shin I. *J Am Chem Soc.* 2004; 126:4812–4819. [PubMed: 15080685]
374. Tully SE, Rawat M, Hsieh-Wilson LC. *J Am Chem Soc.* 2006; 128:7740–7741. [PubMed: 16771479]
375. Disney MD, Seeberger PH. *Chem Biol.* 2004; 11:1701–1707. [PubMed: 15610854]
376. Wang DN, Liu SY, Trummer BJ, Deng C, Wang AL. *Nat Biotechnol.* 2002; 20:275–281. [PubMed: 11875429]
377. Muramatsu T. *J Biochem.* 2002; 132:359–371. [PubMed: 12204104]
378. Huang EJ, Reichardt LF. *Annu Rev Neurosci.* 2001; 24:677–736. [PubMed: 11520916]
379. Nandini CD, Mikami T, Ohta M, Itoh N, Akiyama-Nambu F, Sugahara K. *J Biol Chem.* 2004; 279:50799–50809. [PubMed: 15385557]

380. de Paz JL, Angulo J, Lassaletta JM, Nieto PM, Redondo-Horcajo M, Lozano RM, Gimenez-Gallego G, Martin-Lomas M. *ChemBioChem*. 2001; 2:673–685. [PubMed: 11828504]
381. Prusiner SB. *Science*. 1991; 252:1515–1522. [PubMed: 1675487]
382. Selkoe DJ. *Neuron*. 1991; 6:487–498. [PubMed: 1673054]
383. Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang ZW, Fletterick RJ, Cohen FE, Prusiner SB. *Proc Natl Acad Sci USA*. 1993; 90:10962–10966. [PubMed: 7902575]
384. Safar J, Roller PP, Gajdusek DC, Gibbs CJ. *J Biol Chem*. 1993; 268:20276–20284. [PubMed: 8104185]
385. Perez M, Wandosell F, Colaco C, Avila J. *Biochem J*. 1998; 335:369–374. [PubMed: 9761736]
386. Buee L, Ding WH, Anderson JP, Narindrasorasak S, Kisilevsky R, Boyle NJ, Robakis NK, Delacourte A, Greenberg B, Fillit HM. *Brain Res*. 1993; 627:199–204. [PubMed: 8298962]
387. Buee L, Ding W, Delacourte A, Fillit H. *Brain Res*. 1993; 601:154–163. [PubMed: 8431762]
388. Fraser PE, Nguyen JT, Chin DT, Kirschner DA. *J Neurochem*. 1992; 59:1531–1540. [PubMed: 1402902]
389. Snow AD, Wight TN. *Neurobiol Aging*. 1989; 10:510–512.
390. Snow AD, Lara S, Nochlin D, Wight TN. *Acta Neuropathol*. 1989; 78:113–123. [PubMed: 2473592]
391. Snow AD, Kinsella MG, Prather PB, Nochlin D, Podlisny MB, Selkoe DJ, Kisilevsky R, Wight TN. *J Neuropathol Exp Neurol*. 1989; 48:352–352.
392. Guptabansal R, Frederickson RCA, Brunden KR. *J Biol Chem*. 1995; 270:18666–18671. [PubMed: 7629198]
393. Shaffer LM, Dority MD, Guptabansal R, Frederickson RCA, Younkin SG, Brunden KR. *Neurobiol Aging*. 1995; 16:737–745. [PubMed: 8532106]
394. Shaffer LM, Dority MD, Younkin SG, Brunden KR. *Neurobiol Aging*. 1994; 15:S152–S152.
395. Snow AD, Sekiguchi R, Nochlin D, Fraser P, Kimata K, Mizutani A, Arai M, Schreier WA, Morgan DG. *Neuron*. 1994; 12:219–234. [PubMed: 8292358]
396. Leveugle B, Ding W, Durkin JT, Mistretta S, Eisle J, Matic M, Siman R, Greenberg BD, Fillit HM. *Neurochem Int*. 1997; 30:543–548. [PubMed: 9152995]
397. Leveugle B, Ding WH, Laurence F, Dehouck MP, Scanameo A, Cecchelli R, Fillit H. *J Neurochem*. 1998; 70:736–744. [PubMed: 9453569]
398. Walzer M, Lorens S, Hejna M, Fareed J, Hanin I, Cornelli U, Lee JM. *Eur J Pharmacol*. 2002; 445:211–220. [PubMed: 12079686]
399. Dudas B, Cornelli U, Lee JM, Hejna MJ, Walzer M, Lorens SA, Mervis RF, Fareed J, Hanin I. *Neurobiol Aging*. 2002; 23:97–104. [PubMed: 11755024]
400. Avila J. *FEBS Lett*. 2006; 580:2922–2927. [PubMed: 16529745]
401. Bergamaschini L, Donarini C, Rossi E, De Luigi A, Vergani C, De Simoni MG. *Neurobiol Aging*. 2002; 23:531–536. [PubMed: 12009502]
402. Leveugle B, Scanameo A, Ding W, Fillit H. *Neuroreport*. 1994; 5:1389–1392. [PubMed: 7522615]
403. Aisen PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, Garceau D. *Neurology*. 2006; 67:1757–1763. [PubMed: 17082468]


Biographies




Heather E. Murrey received a B.A./M.S. degree in biochemistry from Brandeis University in 2000. She then conducted research at the Whitehead Institute for Biomedical Research in the laboratories of Peter S. Kim and Harvey F. Lodish. She is currently pursuing a Ph.D. at Caltech under the direction of Linda C. Hsieh-Wilson. Her graduate studies have focused on the role of fucosyl oligosaccharides in neuronal communication and development.



Linda C. Hsieh-Wilson received her B.S. degree in chemistry from Yale University in 1990. She then earned her Ph.D. degree in 1996 from the University of California at Berkeley, where she worked with Peter G. Schultz. After completing postdoctoral studies in neurobiology at The Rockefeller University with Nobel Laureate Paul Greengard in 2000, she joined the faculty at the California Institute of Technology, where she is currently Associate Professor of Chemistry. In 2005, she was appointed a Howard Hughes Medical Institute Investigator. Her research group works at the interface of organic chemistry and neurobiology to study the roles of carbohydrates and their associated proteins in transcription, neuronal signaling, and brain development.

**Figure 1.**


Common structures of sialic acid derivatives: neuraminic acid (Neu), *N*-acetylneuraminic acid (Neu5Ac), *N*-glycolylneuraminic acid (Neu5Gc), and deaminoneuraminic acid (KDN).



Ganglioside	Nomenclature
GD1a , R ₁ = H, R ₂ = H	Neu5Acα(2-3)Galβ(1-3)GalNAcβ(1-4)[Neu5Acα(2-3)]Galβ(1-4)Glc(1-1')Cer
GT1b , R ₁ = Neu5Ac, R ₂ = H	Neu5Acα(2-3)Galβ(1-3)GalNAcβ(1-4)[Neu5Acα(2-8)Neu5Acα(2-3)]Galβ(1-4)Glc(1-1')Cer
GQ1bα , R ₁ = Neu5Ac, R ₂ = Neu5Ac	Neu5Acα(2-3)Galβ(1-3)[Neu5Acα(2-3)GalNAcβ(1-4)[Neu5Acα(2-8)Neu5Acα(2-3)]Galβ(1-4)Glc(1-1')Cer

Figure 2.

Structures of gangliosides that bind to MAG. Neu5Ac = *N*-acetylneuramic acid; Gal = galactose; GalNAc = *N*-acetylgalactosamine; Glc = glucose; Cer = ceramide.




Attenuate Binding		
Compound	R ₁	R ₂
1	H	CH ₃ CO
2	Cl	CH ₃ CO
3	Br	CH ₃ CO
4	I	CH ₃ CO
5	SH	CH ₃ CO

Enhance Binding		
Compound	R ₁	R ₂
6	⁺ NH ₃	CH ₃ CO
7	OH	CH ₃ CH ₂ CO
8	OH	NH ₂ CH ₂ CO
9	OH	CH ₃ CS
10	OH	FCH ₂ CO
11	OH	ClCH ₂ CO
12	OH	BrCH ₂ CO
13	OH	CF ₃ CO

Figure 3.

Synthetic sialic acid analogues tested for binding to MAG. Positions important for MAG interactions are shown in red.



Neu5Ac α (2-3)Gal β (1-3)[Neu5Ac α (2-6)]GalNAc α -O-ThrOCH₃





Figure 4.

Structure of (A) a potent disialyl MAG inhibitor and (B) a simplified mimic of the ganglioside GQ1ba with enhanced binding affinity to MAG relative to Neu5Ac α (2-3)Gal β (1-3)-GalNAc.

**Figure 5.**

(A) Mannosamine derivatives used for metabolic labeling (R = H or Ac) and (B) chemoselective labeling reaction after treatment of cells with ManLev (R = biotin).




Figure 6.
Structures of various fucose derivatives and 2-dGal.




Figure 7.

Inhibition of $\text{Fuca}(1\text{--}2)\text{Gal}$ linkages with 2-dGal leads to stunted neurite outgrowth in hippocampal neurons cultured for 4 days *in vitro* (DIV). D-Gal is able to rescue the effects of 2-dGal. 3-dGal has no effect. White bar indicates $45\ \mu\text{m}$. Images courtesy of C. Gama.




Figure 8.

Chemical probe for imaging lectin receptors (top) and staining of hippocampal neurons in culture (bottom panels) with the probe demonstrating the presence of Fuc α (1–2)Gal lectins along the cell body and neurites. Cells were treated with 3 mM of the imaging probe (A) or biotin (B), labeled with a streptavidin–dye conjugate, and imaged by fluorescence microscopy. Images courtesy of C. Gama.





Figure 9.
O-GlcNAc glycosylation.

**Figure 10.**

(A) Chemoenzymatic approach for tagging O-GlcNAc glycosylated proteins, (B) UDP-azidogalactose probe for [3 + 2] cycloaddition chemistry using the chemoenzymatic approach, and (C) GlcNAz and biotin phosphine probe for metabolic labeling of O-GlcNAc-modified protein using the Staudinger ligation.




Figure 11.
BEMAD approach for mapping *O*-GlcNAc glycosylation sites.




Figure 12.

A fluorescence resonance energy transfer (FRET)-based sensor to detect *O*-GlcNAc glycosylation levels.




Figure 13.

QUIC-Tag approach for quantifying dynamic changes in glycosylation.





**Alloxan****PUGNAc****Nagstatin Derivative****GlcNAc-Thiazoline Derivatives**

Figure 14.
Small-molecule OGA inhibitors.

**Figure 15.**

Structures of GAG subclasses. Potential sulfation sites are indicated in red. $R = \text{SO}_3^-$ or H ; $R_1 = \text{SO}_3^-$, H , or Ac ; $n = \sim 10\text{--}200$.




Figure 16.

CS-E, -A, -C, and -R tetrasaccharides. Only the CS-E tetrasaccharide promotes neurite outgrowth.